

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

AT E1 V1 X0 DT93592500  
CONNECT

f  
Dialog Information Services' DIALNET  
-2030:01-021-  
Enter Service: DIALOG

DIALNET: call connected

DIALOG INFORMATION SERVICES  
PLEASE LOGON:

\*\*\*\*\* HHHHHHH SSSSSSS ? \*\*\*\*\*  
ENTER PASSWORD:

\*\*\*\*\* HHHHHHH SSSSSSS ? \*\*\*\*\*

Welcome to DIALOG  
Dialog level 29.01.09D

Last logoff: 26jan93 16:09:03  
Logon file001 04feb93 11:15:36  
COPY. (c) DIALOG INFORMATION SERVICES, INC. ALL RIGHTS RESERVED.  
NO CLAIM TO ORIG. U.S. GOVT. WORKS.

New: VIRGINIAN-PILOT/LEDGER-STAR (PAPERS) (File 741)  
New: IMSHORLD R & D FOCUS (File 445) - Bluesheet available  
online in File 415

\*\*\*TEXTLINE Files Restructured to TEXTLINE GLOBAL NEWS\*\*\*  
(Files 799, 772, 771)  
\*\*\*Now Available - DIALOG BANK Command\*\*\*

))) Enter BEGIN HOWEASE for Dialog Announcements (((  
))) of new databases, price changes, etc. (((

File 1:ERIC 66-93/JAN

Set Items Description

?b 155,50,55,144,76

04feb93 11:16:05 User219509 Session D70.1

00.29 0.008 Hrs File1  
00.29 Estimated cost File1  
00.00 DIALNET  
00.30 Estimated cost this search  
00.20 Estimated total session cost 0.008 Hrs.

SYSTEM:OS - DIALCS OneSearch

File 155:MEDLINE 1966-1993/MAR (9303W4)

File 50:CAB Abstracts 1984-1993/Jan

(c) 1993 CAB International

\*\*FILE050: COPR. 1990 CABI. See HELPNEWS50 for CAB training schedule.

File 55:BIOSIS PREVIEWS 85-93/JAN BA9504:BARRM4404

(C. BIOSIS 1993)

\*\*FILE 55: Biosystematic Codes (BC=) for viruses have changed for 1993.

Type ?NEWS55 for more information and a complete list of the new codes.

File 144:PASCAL 1973 - 1992 DEC

(C. INIST/CNRS 1992)

\*\*FILE144: Limit problem: see ?news144

Update 9301 has been temporarily backed off due to duplicate records

File 76:LIFE SCIENCES COLLECTION 70-92/DEC

(Copr. Cambridge Scientific Abs.)

Set Items Description

?b 155,50,55,144,72,350,351

04feb93 11:16:36 User219509 Session D70.2

00.03 0.001 Hrs File155  
00.03 Estimated cost File155  
00.06 0.001 Hrs File50  
00.06 Estimated cost File50  
00.10 0.001 Hrs File55  
00.10 Estimated cost File55  
00.06 0.001 Hrs File144  
00.06 Estimated cost File144  
00.09 0.001 Hrs File76  
00.09 Estimated cost File76  
OneSearch, 5 files, 0.003 Hrs File05  
00.09 DIALNET  
00.43 Estimated cost this search  
00.61 Estimated total session cost 0.016 Hrs.

SYSTEM:CS - DIALOG OneSearch  
 File 155:NEELINE 1966-1992/MAR (93C3W4)  
 File 52:CAR Abstracts 1984-1993/Jun  
 (c) 1993 CAB International  
 \*\*FILE55: COPR. 1990 CABI. See XELPNEWS55 for CAR training  
 schedule.  
 File 55:BIOSIS PREVIEWS 85-93/JAN BA9524:BARRM4424  
 (C. BIOSIS 1993)  
 \*\*FILE 55: Biosystematic Codes (BC=) for viruses have changed  
 for 1993.  
 Type ?NEWS55 for more information and a complete list of the new  
 codes.  
 File 144:PASCAL 1973 - 1992 DEC  
 (C. INIST/CNRS 1992)  
 \*\*FILE144: Limit problem: see ?news144  
 Update 9301 has been temporarily backed off due to duplicate  
 records  
 File 72:EMBASE (EXCERPTA MEDICA) 85-93/IS225  
 (COPR. ESP BV/EM 1993)  
 \*\*FILE 72: Truncate ENTREE Codes (e.g. DC=C1.120?) for complete  
 retrieval. The 9245 update has been added.  
 File 350:Derwent World Patents Index  
 1963-1990, EQUIVALENTS THRU DW=9247  
 \*\*FILE350: Format 9 includes the expanded patent table.  
 Preformatted  
 REPORTs are available. Type ?FMT350, ?NEWS350, ?RATES350 for  
 more info.  
 File 351:DERWENT WORLD PATENTS INDEX-LATEST  
 1981+;DW=9251,UA=9239,UM=9208  
 \*\*FILE351: Format 9 includes the expanded patent table.  
 Preformatted  
 REPORTs are available. Type ?FMT351, ?NEWS351, ?RATES351 for

more info.

Set	Items	Description
-----	-------	-------------

?s antivenin

S1	591	ANTIVENIN
----	-----	-----------

?s s1 and ( f(ab) or fab fragment or f(ab)2)

	591	S1
	0	F(AB)
	4	FAB FRAGMENT
	0	F(AB)2
S2	0	S1 AND ( F(AB) OR FAB FRAGMENT OR F(AB)2)

?s s1 and ( f(ab) or fab(w)fragment or fab or fab2 )

	591	S1
	0	F(AB)
	19255	FAB
	133720	FRAGMENT
	2039	FAB(W)FRAGMENT

78 FAB2  
 S3 2 S1 AND ( F(AB) OR FAB(W)FRAGMENT OR FAB OR FAB2  
 )  
 ?t s3/3/1,2

3/3/1 (Item 1 from file: 155)  
 06089508 87063508  
 Immunotherapy in the poisoned patient. Overview of present  
 applications  
 and future trends.  
 Sullivan JB Jr  
 Med Toxicol Jan-Feb 1986, 1 (1) p47-60, ISSN 0112-5966  
 Journal Code: MDT  
 Languages: ENGLISH  
 Document type: JOURNAL ARTICLE; REVIEW

3/3/2 (Item 1 from file: 144)  
 10276259 PASCAL No.: 92-048217C  
 An affinity purified ovine antivenom for the treatment of  
 Vipera berus  
 envenoming  
 SMITH D C; REDDI K R; LAING G; THEAKSTON R G D; LONDON J  
 Therapeutic Antibodies Inc., St. Bartholomew's hosp. medical  
 school,  
 London, United Kingdom  
 Journal: Toxicon : (Oxford), 1992, 30 (8) 865-871  
 Language: English  
 ?ds

Set Items Description

S1 591 ANTIVENIN  
 S2 0 S1 AND ( F(AB) OR FAB FRAGMENT OR F(AB)2)  
 S3 2 S1 AND ( F(AB) OR FAB(W)FRAGMENT OR FAB OR FAB2 )

?s venom

S4 23062 VENOM  
 ?s fab or fab2

19255 FAB  
 78 FAB2  
 S5 19302 FAB OR FAB2  
 ?s s4 and s5

23062 S4  
 19302 S5  
 S6 72 S4 AND S5  
 ?rd

)))Duplicate detection is not supported for File 350.  
 )))Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)  
...completed examining records  
57 42 RD (unique items)  
?t s7/3/1-40

7/3/1 (Item 1 from file: 155)  
08306233 93016233

Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice.

Pimm MV; Gribben SJ  
Cancer Research Campaign Laboratories, University of Nottingham, UK.

J Cancer Res Clin Oncol (GERMANY) 1992, 119 (1) p41-5, ISSN 0171-5216

Journal Code: HLE

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/2 (Item 2 from file: 155)  
08259347 92397347

An affinity purified ovine antivenom for the treatment of Vipera berus envenoming.

Smith DC; Reddi KR; Laing G; Theakston RG; Landon J  
Therapeutic Antibodies Inc., St. Bartholomew's Hospital Medical School,

London, U.K.  
Toxicol (ENGLAND) Aug 1992, 30 (8) p865-71, ISSN 0041-0101  
Journal Code: VWT  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

7/3/3 (Item 3 from file: 155)  
08248192 92386192

Limited proteolysis of human and rabbit immunoglobulins by snake venoms produces Fab-like fragments.

Assakura MT; Mandelbaum FR  
Servico de Bioquimica, Instituto Butantan, Sao Paulo, Brasil.  
Braz J Med Biol Res (BRAZIL) 1990, 23 (12) p1233-5, ISSN 0100-879X

Journal Code: BOF

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/4 (Item 4 from file: 155)  
07995510 92033510

hepatic veno-occlusive disease in a patient with type  
anticoagulant  
after allogeneic bone marrow transplantation.  
Morio S; Oh H; Mirasawa A; Aotsuka M; Nakamura H; Asai T;  
Yoshida S; Ito

M

Second Department of Internal Medicine, School of  
Medicine, Chiba  
University, Japan.

Bone Marrow Transplant (ENGLAND) Aug 1991, 8 (2)  
p147-9, ISSN

0268-2369 Journal Code: BON

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/2/5 (Item 5 from file: 155)

07885296 92023296

Neutralization of kinin-releasing enzymes of crotalid  
venoms by  
monospecific and polyspecific antivenoms.

Bailey GS; al-Joufi A; Rawat S; Smith DC

Department of Chemistry and Biological Chemistry, University  
of Essex,  
Colchester, U.K.

Toxicon 1991, 29 (6) p777-81, ISSN 0041-0101 Journal  
Code: VMT

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/6 (Item 6 from file: 155)

07804536 91323536

Crystallization and preliminary X-ray diffraction data of  
the Fab

fragment of a monoclonal antibody against apazin, a bee venom  
neurotoxin.

Devaux C; Defendini ML; Alzar PM; Abergel C; Granier C;  
Fontecilla-Camps

JC

Laboratoire de Biochimie, CNRS URA 1455, Faculte de  
Medecine-Nord,  
Marseille, France.

FEBS Lett Jul 29 1991, 286 (1-2) p64-6, ISSN 0014-5793

Journal Code: EUH

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/7 (Item 7 from file: 155)

07552443 91071443

A new small myotoxin from the venom of the prairie rattlesnake  
(Crotalus  
viridis viridis).

Griffin PR; Bird SD

California Institute of Technology, Division of Biology,  
Pasadena 91125.

FEBS Lett Nov 12 1990, 274 (1-2) p43-7, ISSN 0014-5793

Journal Code: EBM  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

7/3/8 (Item 8 from file: 155)

07522655 91042655

Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')<sub>2</sub>-cobra venom factor conjugate are equally cytotoxic.

Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW

Department of Biochemistry and Molecular Biology, Georgetown University,  
Washington, DC 20007.

Mol Immunol Oct 1990, 27 (10) p957-64, ISSN 0161-5890

Journal Code: NG1

Contract/Grant No.: CA 35525; CA 01039

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/9 (Item 9 from file: 155)

07476500 90335500

Cleavage of immunoglobulins by moojeni protease A, from the venom of

Bothrops moojeni.

Assakura MT; Mandelbaum FR

Servico de Bioquimica, Instituto Butantan, Sao Paulo, Brasil.

Toxicol 1990, 28 (6) p734-6, ISSN 0041

-0101 Journal Code: VWT

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/10 (Item 10 from file: 155)

07060610 89362610

Immunotoxicotherapy: present status and future trends.

Scherrmann JM; Terrien N; Urtizberea M; Pierson P; Denis R; Bourre JM

InsERM U.26, Hopital Fernand Widal, Paris, France.

J Toxicol Clin Toxicol 1999, 27 (1-2) p1-35, ISSN 0731-3910

Journal Code: KAN

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

7/3/11 (Item 11 from file: 155)

06909841 09291041

Molecular recognition in the activation of human blood coagulation factor

X.

Chattopadhyay A; Fair DS

Department of Biochemistry, University of Texas Health

75710.  
J Biol Chem Jul 5 1989, 264 (19) p11035-43, ISSN 0021-9258  
Journal Code: H10  
Contract/Grant No.: HL 39040  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

7/3/12 (Item 12 from file: 155)  
06955725 89267705  
Purification of F(ab')<sub>2</sub> anti-snake venom by caprylic acid: a fast method  
for obtaining IgG fragments with high neutralization activity, purity and yield.

dos Santos MC; D'Imperio Lima MR; Furtado GC; Collette GM; Kipnis TL;  
Dias da Silva W

Fundacao Ezequiel Dias, Universidade Federal de Minas Gerais, Brazil.

Toxicon 1989, 27 (3) p297-303, ISSN 0041-0101 Journal  
Code: VMT  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

7/3/13 (Item 13 from file: 155)  
06869252 89171252  
Neutralization of lethal potency and inhibition of enzymatic activity of  
a phospholipase A<sub>2</sub> neurotoxin, crotoxin, by non-precipitating antibodies  
(Fab).

Chouret V; Jiang NS; Radvanyi F; Ownby C; Bon C

Laboratoire des Venins, Institut Pasteur, Paris, France.  
FEBS Lett Feb 13 1989, 244 (1) p167-73, ISSN 0014-5793  
Journal Code: EUH  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

7/3/14 (Item 14 from file: 155)  
06525042 88170042  
Decay-accelerating factor protects human tumor cells from  
complement-mediated cytotoxicity in vitro.  
Cheung NK; Walter EI; Smith-Mensah WH; Ratnoff WD; Tykocinski ML; Medof ME

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York 10021.

J Clin Invest Apr 1988, 81 (4) p1122-9, ISSN 0021-9732  
Journal Code: M57  
Contract/Grant No.: CA-39320, AI-24220, AI-20590  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

7/3/15 (Item 15 from file: 155)

06353393 00203393

Block of synaptic transmission in insect CNS by toxins from  
the venom of

the wasp *Megascolia flavifrons* (Fab.).

Piek T; Hue B; Morry L; Nakajima T; Palhato M; Yasuhara T

Department of Pharmacology, University of Amsterdam, The  
Netherlands.

Comp Biochem Physiol [C] 1987, 87 (2) p287-95, ISSN  
0742-8413

Journal Code: DNX

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/16 (Item 16 from file: 155)

06089508 07063508

Immunotherapy in the poisoned patient. Overview of present  
applications

and future trends.

Sullivan JB Jr

Med Toxicol Jan-Feb 1986, 1 (1) p47-60, ISSN 0112-5966

Journal Code: MD7

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW

7/3/17 (Item 17 from file: 155)

06035955 07009955

Defining the role of complement in experimental pemphigus  
vulgaris in  
mice.

Anhalt GJ; Till GO; Diaz LA; Labib RS; Patel HP; Eaglstein NF

J Immunol Nov 1 1986, 137 (9) p2835-40, ISSN 0022-1767

Journal Code: IFB

Contract/Grant No.: R23-AM32490; R23-AM32279; R01-AM32599; +

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/18 (Item 18 from file: 155)

05549020 05265020

Role of complement and the Fc portion of immunoglobulin G in  
immunity to

Venezuelan equine encephalomyelitis virus  
infection with

glycoprotein-specific monoclonal antibodies.

Mathews JH; Roehrig JT; Trent DM

J Virol Sep 1985, 55 (3) p594-600, ISSN 0022-538X Journal

Code: KCV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/19 (Item 19 from file: 155)

05534749 05150749

Modulation of endotoxin-induced haemodynamic and

haematological changes  
in the rabbit by methylprednisolone, F(ab')<sub>2</sub> fragments and  
ascorbic acid.

Bult H; Herman AG; Raapart M

Dr J Pharmacol Feb 1985, 84 (2) p317-27, 1st 57/3/9-42

SN 0007-1188

Journal Code: B02

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/20 (Item 20 from file: 155)

05412032 85026032

Magascoliakinin, a bradykinin-like compound in the venom of  
Megascolia

flavifrons Fab. (Hymenoptera: Scolidae).

Piek T; Mantel P; Van Ginkel CJ

Comp Biochem Physiol 1984, 78 (2) p473-4, ISSN

0742-9413

Journal Code: DNX

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/21 (Item 21 from file: 155)

04706845 82249845

Neurotoxin-specific immunoglobulins accelerate  
dissociation of the  
neurotoxin-acetylcholine receptor complex.

Boulain JC; Menez A

Science Aug 20 1982, 217 (4561) p732-3, ISSN 0036-8075

Journal Code: UJ7

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/22 (Item 22 from file: 155)

04228391 81056391

Inhibition of biological activity of mouse beta-nerve growth  
factor by  
monoclonal antibody.

Warren SL; Fanger M; Neet KE

Science Nov 21 1980, 210 (4472) p910-2, ISSN 0036-8075

Journal Code: UJ7

Contract/Grant No.: A110148; CA27915

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/22 (Item 23 from file: 155)

04183515 81011516

Immunopharmacological approach to Forssman shock.

Nagai H; Kuwazoto Y; Koda A

Microbiol Immunol 1980, 24 (7) p649-55, Journal Code: MX7

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/22 (Item 24 from file: 155)

04060395 00174695

Immune retention: immunological requirements for maintaining  
an easily  
degradable antigen in vivo.

Tew JG; Mandel TE; Miller SA

Aust J Exp Biol Med Sci Aug 1979, 57 (4) p401-14, ISSN  
0004-945X

Journal Code: 9FW

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/2/25 (Item 25 from file: 155)

03671494 79248494

Immunological studies on pancreatic phospholipase A2.  
Antigenic  
characterization of the NH2-terminal region.

Meijer W; Meddens MJ; Dijkman R; Slotboom AJ; de Haas EH

J Biol Chem Dec 10 1978, 253 (23) p2564-9, ISSN 0321-9258

Journal Code: HIV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/26 (Item 26 from file: 155)

02909946 76090946

Guinea-pig nephrotoxic nephritis. I. The role of  
complement and  
polymorphonuclear leucocytes and the effect of antibody  
subclass and  
fragments in the heterologous phase.

Simpson LJ; Amos N; Evans DJ; Thomson NM; Peters DK

Clin Exp Immunol Mar 1975, 19 (3) p499-511, ISSN 0009-9104

Journal Code: DD7

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/27 (Item 1 from file: 55)

9149815 BIOSIS Number: 93134215

NOVEL QUATERNARY AMMONIUM SALT-CONTAINING POLYAMINES FROM THE  
AGELENOPSIS-APERTA FUNNEL-WEB SPIDER

JASYS V J; KELBAUGH P R; NASON D M; PHILLIPS D; ROSNACK K J;  
FORMAN J T;

SACCOMAND N A; STROH J S; VOLKMAN R A

CENTRAL RESEARCH DIVISION, PFIZER INC., GROTON, CONN. 06340.

J ORG CHEM 57 (6). 1992. 1814-1820. CODEN: JOCEA

Full Journal Title: Journal of Organic Chemistry

Language: ENGLISH

7/2/29 (Item 2 from file: 55)

9128209 BIOSIS Number: 93123809

CORRECTION OF BA 92098484. CRYSTALLIZATION AND PRELIMINARY  
X-RAY

DIFFRACTION DATA OF THE FAB FRAGMENT OF A MONOCLONAL ANTIBODY  
AGAINST

ADAMTS A REVERSE NEURONICIN CORRECTION OF ADAMTS HAVE FROM

ALZARI P M; DEFENDINI M-L; ABERSEL C; GRANIER C;  
FONTECILLA-CAMPS J C  
LAB. BIOCHEM., FAC. MED.-NORD, BOULEVARD PIERRE DRAMARD, 13326  
MARSEILLE  
CEDEX 15, FR.  
FEBS (FED EUR BIOCHEM SOC) LETT 285 (1/2). 1991. 64-66.  
CODEN: FEBLA

1-2. 1991. P. 307

Full Journal Title: FEBS (Federation of European Biochemical Societies)  
Letters  
Language: ENGLISH

7/3/29 (Item 3 from file: 55)

8558708 BIOSIS Number: 92023708

A SANDWICH ENZYME-IMMUNASSAY FOR DETECTING SNAKE VENOM

GE B; YU H; WANG J; XU Y

SHANGHAI INST. BIOCHEMISTRY, ACADEMIA SINICA.

ZOOL RES 12 (1). 1991. 79-83. CODEN: ZOYAD

Full Journal Title: Zoological Research

Language: CHINESE

7/3/30 (Item 4 from file: 55)

7749725 BIOSIS Number: 90117725

ISOLATION STRUCTURE ELUCIDATION AND SYNTHESIS OF NOVEL  
HYDROXYLAMINE-CONTAINING POLYAMINES FROM THE VENOM OF THE  
AGELENOPSIS-APERTA SPIDER

JASYS V J; KELBAUGH P R; NASON D M; PHILLIPS D; ROSNACK K J;  
SACCOMANO N

A; STROH J G; VOLKMAN R A

CENTRAL RES., PFIZER INC., GROTON, CONN. 06340.

J AM CHEM SOC 112 (18). 1990. 6696-6704. CODEN: JACSA

Full Journal Title: Journal of the American Chemical Society

Language: ENGLISH

7/3/31 (Item 5 from file: 55)

7110115 BIOSIS Number: 02038860

USING AFFINITY CHROMATOGRAPHY TO ISOLATE ALPHA LATROTOXIN FROM  
THE VENOM

OF THE SPIDER LATROSECTUS-TRIDECIMGUTTATUS

DALIMOV B Z; KAEYMOV SH K; SALIKHOV SH I

A.S. SADIYKOV INST. BIOORG. CHEM., ACAD. SCI. UZB. SSR,  
TASHKENT, USSR.

KHIM PRIR SOEDIN (TASHK) 0 (5). 1983. 679-682. CODEN: KPSUA

Full Journal Title: Khimiya Prirodnykh Soedinenii (Tashkent)

Language: RUSSIAN

7/3/32 (Item 6 from file: 55)

7071659 BIOSIS Number: 87122100

PURIFICATION OF FABV-2 ANTI-SNAKE VENOM BY CAPRYLIC ACID A FAST

FOR OBTAINING IGG FRAGMENTS WITH HIGH NEUTRALIZATION ACTIVITY  
PURITY AND

YIELD

SANTOS M C D; LIMA M R D; FURTADO G C; COLLETTI G M D D; KIPNIS  
T L;

SILVA W D D

DEP. IMMUNOL., INST. CIENCIAS BIOMED., UNIV. SAO PAULO, BRAZIL.

TOXICON 27 (3). 1989. 297-304. CODEN: TOXIA

Full Journal Title: Toxicon

Language: ENGLISH

7/3/33 (Item 1 from file: 144)

10226038 PASCAL No.: 92-0431941

Analysis of a mastoparan P isolated from the hornet (Vespa  
Basalis) venom

by fast atom bombardement mass spectrometry with B/E linked scan

YONG-CHIEN LING; BANG-JI LIU; JIEN-MEHNG LO; CHEW-LANG HO

National Tsing Hua univ., dep. chemistry, Hsinchu 300, Taiwan

Journal: Spectroscopy letters, 1992, 25 (2) 245-255

Language: English

7/3/34 (Item 2 from file: 144)

09555774 PASCAL No.: 91-0346201

Structure and biological activities of a new mastoparan  
isolated from the

venom of the hornet Vespa basalis

CHEW-LANG HO; LING-LING HWANG

Acad. sinica, inst. biological chemistry, Taipei 10798, Taiwan

Journal: Biochemical journal : (London. 1984), 1991, 274 (2)

453-456

Language: English

7/3/35 (Item 3 from file: 144)

09114143 PASCAL No.: 90-0282524

Platelet glycoprotein IIb-IIIa protein antagonists from snake  
venoms:

evidence for a family of platelet-aggregation inhibitors

DENNIS M S; HENZEL W J; PITTI R M; LIPARI M T; NAPIER M A;

DEISHER T A;

BUNTING S; LAZARUS R A

Genentech, Inc., dep. biomolecular chemistry, South San  
Francisco CA

94080, USA

Journal: Proceedings of the National Academy of Sciences of the  
United

States of America (1985), 1990, 87 (7) 2471-2475

Language: English

7/3/36 (Item 1 from file: 72)

8528645 EMBASE No: 92204527

Monoclonal antibodies to toxin II from the scorpion Androctonus  
australis

neutralizing  
capacities  
Yahi N.; Devaux C.; Manouelle P.; Defendini M.-L.; Granier C.  
CNRS URA 1455, Laboratoire de Biochimie, Faculte de  
Medecine Secteur  
Nord, Boulevard Pierre Drazard, 13226 Marseille Cedex 15 France  
TOXICON (United Kingdom), 1992, 33/7 (723-731) CODEN:  
TOXIA ISSN:  
0041-0101 ADONIS ORDER NUMBER: 004101019220753  
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/37 (Item 2 from file: 72)  
0343871 EMBASE No: 92020617  
Neutralization of kinin-releasing enzymes from viperid  
venoms by  
antivenom IgG fragments  
Al-Joufi A.; Bailey G.S.; Reddi K.; Smith E.C.  
Department of Chemistry and Biological Chemistry, University  
of Essex,  
Colchester, Essex CO4 3SQ United Kingdom  
TOXICON (United Kingdom), 1991, 29/12 (1509-1511) CODEN:  
TOXIA ISSN:  
0041-0101 ADONIS ORDER NUMBER: 004101019200223Z  
LANGUAGES: English SUMMARY LANGUAGES: English

7/3/28 (Item 3 from file: 72)  
0310262 EMBASE No: 91040920  
Erratum: Crystallization and preliminary X-ray diffraction  
data of the  
Fab fragment of a monoclonal antibody against apamin, a  
bee venom  
neurotoxin (FEBS Letters (1991) 285 (64-66))

Devaux C.; Defendini M.-L.; Alzar P.M.; Abergel C.;  
Granier C.;  
Fontecilla-Caspas J.C.  
FEBS LETT. (Netherlands), 1991, 282/1-2 (307) CODEN:  
FEELA ISSN:  
0014-5793 ADONIS ORDER NUMBER: 201457939101451L  
LANGUAGES: English

7/3/39 (Item 4 from file: 72)  
0312121 EMBASE No: 07049774  
Use of antibodies specific to defined regions of scorpion  
alpha-toxin to  
study its interaction with its receptor site on the sodium  
channel  
Ayeb E.M.; Bahracui E.M.; Granier C.; Rochet H.  
INSERM U172 and CNRS UA 553, Laboratoire de Biochimie,  
Faculte de  
Medecine Secteur Nord, 13226 Marseille Cedex 15 FRANCE  
BIOCHEMISTRY (USA), 1993, 25/21 (6671-6679) CODEN: BICHA  
LANGUAGES: ENGLISH

7/3/40 (Item 1 from file: 251)

028442348 WPI Acc No: 98-329342/44

XREF Acc No: C90-142975

New poly-amine(s) and polypeptide(s) from spider venom - are excitatory

amino acid neuro-transmitter antagonists and calcium channel blockers

Patent Assignee: (NATU-) NATURAL PROD SCI INC; (PFIZ ) PFIZER INC

Author (Inventor): SACCOMANO N A; VOLKMAN R A

Patent Family:

CC Number	Kind	Date	Week	
EP 095357	A	981031	9044	(Basic)
PT 93976	A	981120	9050	
AU 9054535	A	981100	9101	
NO 9001881	A	981029	9101	
CA 2015505	A	981028	9104	
FI 9002139	A	981029	9107	
JP 3314551	A	910122	9110	
HU T55415	T	910528	9127	
CN 1047078	A	981121	9131	
ZA 9003229	A	911224	9205	
DE 293959	A	910919	9208	
DD 298412	A5	920220	9229	
CS 9002157	A2	920219	9237	

Priority Data (CC No Date): US 345131 (890428)

Applications (CC,No,Date): CS 902157 (900428); EP 90304397 (900424); JP

90115724 (900501); ZA 903229 (900427); DD 343270 (900805)

?

7/3/9 (Item 9 from file: 155)

07478500 90305502

Cleavage of immunoglobulins by scorpion protease A, from the venom of

Bothrops scorpion.

Assakura MT; Mandelbaum ER

Servico de Biotecnologia, Instituto Butantan, Sao Paulo, Brasil.

Toxicol 1990, 28 (5) p734-6, ISSN 0041-0101 Journal Code: WUT

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/10 (Item 10 from file: 155)

07060610 89362610

Immunotoxicotherapy: present status and future trends.

Scherrmann JM; Terrien N; Urtizberea M; Pierson P; Denis M; Bourne JM

Insert U.26, Hopital Fernand Widal, Paris, France.

J Toxicol Clin Toxicol 1989, 27 (1-2) p1-35, ISSN 0731-2910

Journal Code: KAN

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW; TUTORIAL

7/3/11 (Item 11 from file: 155)

26939841 89291841

Molecular recognition in the activation of human blood coagulation factor

X.

Chattopadhyay A; Fair DS

Department of Biochemistry, University of Texas Health Center, Tyler

75710.

J Biol Chem Jul 5 1989, 264 (19) p11035-42, ISSN 0021-9258

Journal Code: HIV

Contract/Grant No.: HL 39040

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/12 (Item 12 from file: 155)

26965725 89267705

Purification of F(ab')<sub>2</sub> anti-snake venom by caprylic acid: a fast method

for obtaining IgG fragments with high neutralization activity, purity and yield.

dos Santos MC; D'Isperio Lisa MS; Furtado GC; Collette CM; Kipnis TL;

Dias da Silva W

Fundacao Ezequiel Dias, Universidade Federal de Minas Gerais, Brazil.

Toxicon 1989, 27 (3) p297-303, ISSN 0041-0101 Journal Code: VMT

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/13 (Item 13 from file: 155)

26869252 89171252

Neutralization of lethal potency and inhibition of enzymatic activity of

a phospholipase A<sub>2</sub> neurotoxin, crotoxin, by non-precipitating antibodies

(Fab).

Choumet V; Jiang MS; Radvanyi F; Canby D; Bon C

Laboratoire des Venins, Institut Pasteur, Paris, France.

FEBS Lett Feb 13 1989, 244 (1) p167-73, ISSN 0214-5793

Journal Code: EUM

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/14 (Item 14 from file: 155)

26525042 89170042

Decay-accelerating factor protects human tumor cells from

complement-mediated cytotoxicity in vitro.

Cheung MK; Walter EI; Smith-Mansah WM; Ratnoff WD; Tykocinski ML; Medof

ME

Department of Pediatrics, Memorial Sloan Kettering Cancer  
Center, New  
York 10021.

J Clin Invest Apr 1988, 81 (4) p1122-8, ISSN 0021-9738

Journal Code: HS7

Contract/Grant No.: CA-39320; AI-24220; AI-23598

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/15 (Item 15 from file: 155)

06350393 86003393

Block of synaptic transmission in insect CNS by toxins from  
the venom of  
the wasp *Megascolia flavifrons* (Fab.).

Piek T; Hue B; Mony L; Nakajima T; Pelhate M; Yasuhara T

Department of Pharmacology, University of Amsterdam, The  
Netherlands.

Comp Biochem Physiol [C] 1987, 87 (2) p287-95, ISSN  
0742-8413

Journal Code: DNX

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/16 (Item 16 from file: 155)

06089508 87063508

Immunotherapy in the poisoned patient. Overview of present  
applications  
and future trends.

Sullivan JB Jr

Med Toxicol Jan-Feb 1986, 1 (1) p47-60, ISSN 0112-5966

Journal Code: MDT

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW

7/3/17 (Item 17 from file: 155)

06035955 87009955

Defining the role of complement in experimental pemphigus  
vulgaris in  
mice.

Anhalt GJ; Till GO; Diaz LA; Latib RS; Patel HP; Eaglstein NF

J Immunol Nov 1 1986, 137 (9) p2835-40, ISSN 0022-1767

Journal Code: IFB

Contract/Grant No.: R23-AM32490; R23-AM32079; R01-AM32599; +

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/18 (Item 18 from file: 155)

05649020 85265020

Role of complement and the Fc portion of immunoglobulin G in  
immunity to

Venezuelan equine encephalomyelitis virus  
infection with

glycoprotein-specific monoclonal antibodies.

J Virol Sep 1985, 55 (3) p594-600, ISSN 0022-538X Journal  
Code: KCV  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

7/3/19 (Item 19 from file: 155)  
05534749 85150749  
Modification of endotoxin-induced haemodynamic and  
haematological changes  
in the rabbit by methylprednisolone, F(ab')<sub>2</sub> fragments and  
rosmarinic acid.  
Bult H; Herman AG; Rampart M  
Br J Pharmacol Feb 1985, 84 (2) p317-27, ISSN 0007-1188  
Journal Code: B00  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

7/3/20 (Item 20 from file: 155)  
05410032 85026032  
Megascoliakinin, a bradykinin-like compound in the venom of  
Megascolia  
flavifrons Fab. (Hymenoptera: Scoliidæ).  
Piek T; Mantel P; Van Ginkel CJ  
Comp Biochem Physiol [C] 1984, 78 (2) p473-4, ISSN  
0742-8413  
Journal Code: DNX  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

7/3/21 (Item 21 from file: 155)  
04706845 82249845  
Neurotoxin-specific immunoglobulins accelerate

dissociation of the  
neurotoxin-acetylcholine receptor complex.  
Boulain JC; Menez A  
Science Aug 20 1982, 217 (4561) p732-3, ISSN 0036-8075  
Journal Code: UJ7  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

7/3/22 (Item 22 from file: 155)  
04228391 81056391  
Inhibition of biological activity of mouse beta-nerve growth  
factor by  
monoclonal antibody.  
Warren SL; Fanger N; Neet KE  
Science Nov 21 1986, 210 (4472) p910-2, ISSN 0036-8075  
Journal Code: UJ7  
Contract/Grant No.: A110148; CA27915  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

7/3/23 (Item 23 from file: 155)  
0412514 81011514

Immunopharmacological approach to Foreman shock.

Nagai H; Munimoto Y; Koda A

Microbiol Immunol 1980, 24 (7) p649-55, Journal Code: MX7

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/84 (Item 24 from file: 155)

24053605 00174595

Immune retention: immunological requirements for maintaining an easily

degradable antigen in vivo.

Tew JB; Mandel TE; Miller GA

Aust J Exp Biol Med Sci Aug 1979, 57 (4) p421-14, ISSN

0004-945X

Journal Code: 9FW

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/85 (Item 25 from file: 155)

03571494 79040494

Immunological studies on pancreatic phospholipase A2. Antigenic

characterization of the NH2-terminal region.

Meijer H; Muddens MJ; Dijkman R; Slotboom AJ; de Haas GH

J Biol Chem Dec 10 1978, 253 (23) p8564-9, ISSN 0021-9258

Journal Code: H1V

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/86 (Item 26 from file: 155)

02900946 70000946

Guinea-pig nephrotic nephritis. I. The role of

complement and polymorphonuclear leucocytes and the effect of antibody subclass and fragments in the heterologous phase.

Slapson LJ; Azco N; Evans DJ; Thomson NM; Peters DK

Clin Exp Immunol Mar 1975, 19 (3) p499-511, ISSN 0309-9104

Journal Code: 007

Languages: ENGLISH

Document type: JOURNAL ARTICLE

7/3/87 (Item 1 from file: 55)

9140015 DISCIS Number: 93134815

NOVEL QUATERNARY AMMONIUM SALT-CONTAINING POLYAMINES FROM THE ARACHNID APERTA FUNNEL-WEB SPIDER

JASYS V J; KELBAUGH P R; MADON D M; PHILLIPS D; ROSSACK K J; FORMAN J T;

BRADSHAW N A; STROH J G; VOLKMAN R A

CENTRAL RESEARCH DIVISION, PFIZER INC., GROTON, CONN. 06340.

J ORG CHEM 57 (6), 1992, 1814-1820. CODEN: JOCEA

Full Journal Title: Journal of Organic Chemistry

Language: ENGLISH

7/3/29 (Item 2 from file: 55)  
9138809 BIOSIS Number: 92123809  
CORRECTION OF BA 92038484. CRYSTALLIZATION AND PRELIMINARY  
X-RAY  
DIFFRACTION DATA OF THE FAB FRAGMENT OF A MONOCLONAL ANTIBODY  
AGAINST  
APAMIN A BEE VENOM NEUROTOXIN. CORRECTION OF AUTHOR NAME FROM  
PEDRO M.  
ALZAR. ERRATUM PUBLISHED IN FEBS FED EUR BIOCHEM SOC LETT VOL.  
292. 1991.  
1-2. 1991. P. 307  
DEVAUX C; DEFENDINI M-L; ALZARI P M; ABERGEL C; GRANIER C;  
PONTECILLA-CAMPS J C  
LAB. BIOCHEM., FAC. MED.-NORD, BOULEVARD PIERRE DOMARD, 13326  
MARSEILLE  
CEDEX 15, FR.  
FEBS (FED EUR BIOCHEM SOC) LETT 296 (1/2). 1991. 64-66.  
CODEN: FEELA  
Full Journal Title: FEBS (Federation of European Biochemical  
Societies)  
Letters  
Language: ENGLISH

7/3/29 (Item 3 from file: 55)  
3558723 BIOSIS Number: 92023703  
A SANDWICH ENZYME-IMMUNASSAY FOR DETECTING SNAKE VENOM  
GE B; YU H; WANG J; XU Y  
SHANGHAI INST. BIOCHEMISTRY, ACADEMIA SINICA.  
ZOOLOG RES 12 (1). 1991. 79-83. CODEN: ZOYAD  
Full Journal Title: Zoological Research  
Language: CHINESE

7/3/30 (Item 4 from file: 55)  
7749725 BIOSIS Number: 90117725  
ISOLATION STRUCTURE ELUCIDATION AND SYNTHESIS OF NOVEL  
HYDROXYLAMINE-CONTAINING POLYAMINES FROM THE VENOM OF THE  
ASELENOPSIS-APERTA EPIDER  
JASYS V J; KELBAUGH P R; NASON D M; PHILLIPS D; ROSNACK K J;  
SPACCOMANDO N  
A; STROH J G; VOLKMAN R A  
CENTRAL RES., PFIZER INC., GROTON, CONN. 06340.  
J AM CHEM SOC 112 (19). 1990. 6696-6704. CODEN: JACSA  
Full Journal Title: Journal of the American Chemical Society  
Language: ENGLISH

7/3/31 (Item 5 from file: 55)  
7114115 BIOSIS Number: 90020810  
USING AFFINITY CHROMATOGRAPHY TO ISOLATE ALPHA LATROTOXIN FROM  
THE VENOM  
OF THE EPIDER LATROSECTUS-TREDESDENTATUS  
DALINOV B Z; HASYKOV CH V; DALINOV CH I  
A.S. GRADYKOV INST. BIOORG. CHEM., ACAD. SCI. UZB. SSR,  
TASHKENT, UZSSR.  
RUSSIAN J ZOOL 27 (1990) 2 (5). 1990. 670-672. CODEN: RUZOD

Full Journal Title: Khimiya Prirodnykh Soedinenii (Tashkent)  
Language: RUSSIAN

7/3/32 (Item 6 from file: 55)  
7071659 BICBASE Number: 07122180

PURIFICATION OF FAD'-2 ANTI-COAGULANT VENOM BY CARBOXYLIC ACID A FAST  
METHOD  
FOR OBTAINING 100 FRAGMENTS WITH HIGH NEUTRALIZATION ACTIVITY  
PURITY AND  
YIELD

SANTOS M C D; LIMA M R D; FURTADO S C; COLLETTI S M D D; KIPNIS  
T L;

SILVA W D B

DEP. IMMUNOL., INST. CIENCIAS BIOMED., UNIV. SAO PAULO, BRAZIL.

TOXICON 27 (3). 1989. 297-304. CODEN: TOXIA

Full Journal Title: Toxicon

Language: ENGLISH

7/3/33 (Item 1 from file: 146)

10226038 PASCAL No.: 02-0431941

Analysis of a mastoparan B isolated from the hornet (Vespa  
Basalis) venom

by fast atom bombardement mass spectrometry with B/E linked scan

YONG-CHIEN LING; BANG-JI LIU; JIEN-MENG LO; CHEW-LANG HO

National Tsing Hua univ., dep. chemistry, Hsinchu 300, Taiwan

Journal: Spectroscopy letters, 1992, 25 (2) 245-255

Language: English

7/3/34 (Item 2 from file: 146)

09555774 PASCAL No.: 91-0346201

Structure and biological activities of a new mastoparan

isolated from the  
venom of the hornet Vespa basalis

CHEW-LANG HO; LING-LING HUANG

Acad. sinica, inst. biological chemistry, Taipei 10798, Taiwan

Journal: Biochemical journal : (London, 1984), 1991, 274 (2)  
453-456

Language: English

7/3/35 (Item 3 from file: 146)

03114143 PASCAL No.: 90-0282524

Platelet glycoprotein IIb-IIIa protein antagonists from snake  
venoms:

evidence for a family of platelet-aggregation inhibitors

DENNIS M S; KENZEL W J; PITTI A M; LIPARI M T; NADIER M A;  
ZEISLER T A;

BUNTING S; LAZARUS R A

Genentech, Inc., dep. biocolecular chemistry, South San  
Francisco CA

94022, USA

Journal: Proceedings of the National Academy of Sciences of the  
United

States of America (1995), 1995, 92 (17) 8171-8175

7/3/26 (Item 1 from file: 72)

0520646 EMBASE No: 92004527

Monoclonal antibodies to toxin II from the scorpion *Androctonus australis*

Abstract: Further characterization of epitope specificities and neutralizing capacities

Yahi M.; Devaux C.; Manouelle P.; Defondini M.-L.; Granier C.  
CNRS URA 1455, Laboratoire de Biochimie, Faculté de  
Médecine Soteur

Nord, Boulevard Pierre Dramard, 13326 Marseille Cedex 15 France

TOXICON (United Kingdom), 1992, 20/7 (723-731) CODEN:

TOXIA ISSN:

0241-0101 ADOVIS ORDER NUMBER: 0241010192000752

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/27 (Item 2 from file: 72)

0342871 EMBASE No: 92020517

Neutralization of kinin-releasing enzymes from viperid  
venoms by  
antivenom IgG fragments

Al-Joufi A.; Bailey G.G.; Reddi M.; Smith D.C.

Department of Chemistry and Biological Chemistry, University  
of Essex,

Colchester, Essex CO4 3SQ United Kingdom

TOXICON (United Kingdom), 1991, 29/12 (1509-1511) CODEN:

TOXIA ISSN:

0241-0101 ADOVIS ORDER NUMBER: 0241010192000301

LANGUAGES: English SUMMARY LANGUAGES: English

7/3/29 (Item 3 from file: 72)

0312262 EMBASE No: 91340920

Erratum: Crystallization and preliminary X-ray diffraction  
data of the

Fab fragment of a monoclonal antibody against apamin, a  
bee venom

neurotoxin (FEBS Letters (1991) 286 (64-66))

Devaux C.; Defondini M.-L.; Alzar P.M.; Abargel C.;  
Granier C.;

Fontecilla-Camps J.C.

FEBS LETT. (Netherlands), 1991, 292/1-2 (327) CODEN:

FEPLA ISSN:

0014-5792 ADOVIS ORDER NUMBER: 001457929101451L

LANGUAGES: English

7/3/30 (Item 4 from file: 72)

0313121 EMBASE No: 92040774

Use of antibodies specific to defined regions of scorpion  
alpha-toxin to

study its interaction with its receptor site on the sodium  
channel

Yahi M.; Devaux C.; Manouelle P.; Defondini M.-L.; Granier C.; Soubat M.

INSERM U172 and CNRS UA 553, Laboratoire de Biochimie,  
Faculte de  
Medecine Secteur Nord, 13326 Marseille Cedex 15 FRANCE  
BIOCHEMISTRY (USA), 1986, 25/21 (6671-6678) CODEN: BICHA  
LANGUAGES: ENGLISH

7/3/40 (item 1 from file: 351)

000442348 WPI Acc No: 90-329348/44

XRAW Acc No: C90-142975

New poly-amine(s) and polypeptide(s) from spider venom - are  
eccitatory

amino acid neuro-transmitter antagonists and calcium channel  
blockers

Patent Assignee: (NATU-) NATURAL PROD SCI INC; (PFIZ ) PFIZER INC

Author (Inventor): SACCOMANO N A; VOLKMAN R A

Patent Family:

CC Number	Kind	Date	Week	
EP 395357	A	901031	9044	(Basic)
PT 93876	A	901120	9050	
AU 9054535	A	901108	9101	
NO 9001881	A	901029	9101	
CA 2015505	A	901028	9104	
FI 9002139	A	901029	9107	
JP 3014551	A	910123	9110	
HU T55415	T	910528	9127	
CN 1047078	A	901121	9131	
ZA 9003229	A	911224	9205	
DD 293959	A	910919	9208	
DD 298412	A5	920220	9229	
CS 9002157	A2	920219	9237	

Priority Data (CC No Date): US 346181 (890428)

Applications (CC,No,Date): CS 902157 (900428); EP 90304397  
(900424); JP

90115704 (900501); ZA 903229 (900427); DD 343270 (900806)

?ds

Set	Items	Description
S1	591	ANTIVENIN
S2	0	S1 AND ( F(AB) OR FAB FRAGMENT OR F(AB)2 )
S3	2	S1 AND ( F(AB) OR FAB(W)FRAGMENT OR FAB OR FAB2 )

S4	23062	VENOM
S5	19302	FAB OR FAB2
S6	72	S4 AND S5
S7	40	RD (unique items)

?s s5 and polyacrylamide

19302 S5

145486 POLYACRYLAMIDE

S8 586 S5 AND POLYACRYLAMIDE

? s s8 and (pepsin or papain)

586 S8  
15002 PEPSIN  
10290 PAPAIN

S9 92 S8 AND (PEPSIN OR PAPAIN)

?rd

)))Duplicate detection is not supported for File 350.

)))Duplicate detection is not supported for File 351.

)))Records from unsupported files will be retained in the RD set.

...examined 50 records (50)

...completed examining records

S10 75 RD (unique items)

?t s10/3/1-75

10/3/1 (Item 1 from file: 155)

00177636 92315636

Thiol groups and other chemical characteristics of rat  
monoclonal

immunoglobulin A.

Gertler S; Young NM

Institute for Biological Sciences, National Research Council  
of Canada,

Ottawa, Ontario.

Comp Biochem Physiol [B] (ENGLAND) Jun 1992, 102 (2)

p377-81, ISSN

0305-0491 Journal Code: DNV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/2 (Item 2 from file: 155)

00000766 92218766

Single-step purification of F(ab')<sub>2</sub> fragments of mouse  
monoclonal

antibodies (immunoglobulins G1) by hydrophobic interaction high  
performance

liquid chromatography using TSKgel Phenyl-5PW.

Morimoto K; Inouye K

Biotechnology Research Laboratories, TOSOH Corporation,  
Kanagawa, Japan.

J Biochem Biophys Methods (NETHERLANDS) Mar 1992, 24 (1-2)

p107-17,

ISSN 0165-022X Journal Code: H94

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/3 (Item 3 from file: 155)

07049323 91368323

Dose-dependent reversal of acute murine colchicine  
poisoning by goat

colchicine-specific Fab fragments.

Institut National de la Santé et de la Recherche Médicale  
 U22, Hôpital  
 Fernand Widal, Paris, France.  
 Toxicology 1991; 66 (2) p121-22, ISSN 0362-426X Journal  
 Code: WH  
 Language: ENGLISH  
 Document type: JOURNAL ARTICLE

Journal Code: HIV  
Contract/Grant No.: HL40340; HL44126; HL22217  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE  
10/2/6 (Item 6 from file: 155)  
07691547 91210547  
Proteolytic digestion of mouse IgE.  
Mats S; Misonoff S  
Department of Biology, Brandeis University, Waltham, MA 02254.  
J Immunol Methods Apr 3 1991; 130 (1) p15-22, 100N  
0022-1759  
Journal Code: JSE  
Contract/Grant No.: AI-22068  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/2/77 (Page 7 from file 155)  
07571709 91090709  
The specificity of the IgG receptor purified from human  
neutrophils.

Department of Pathology, University of Dundee, Ninewells  
Hospital Medical  
School, Scotland, U.K.  
Biochem J Nov 15 1990, 272 (1) p159-65, ISSN 0264-6021  
Journal Code: 9Y0  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/8 (Item 8 from file: 155)

07569635 91088635

Preparation and crystallization of a human immunodeficiency  
virus p24-Fab  
complex.

Prongay AJ; Smith TJ; Rossmann MG; Ehrlich LS; Carter CA;  
McClure J

Department of Biological Sciences, Purdue University, West  
Lafayette, IN  
47907.

Proc Natl Acad Sci U S A Dec 1990, 87 (24) p9980-4, ISSN  
0027-8424

Journal Code: PV3

Contract/Grant No.: AI25993; AI27310

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/9 (Item 9 from file: 155)

07552858 91071058

Purification and characterization of an outer membrane  
protein adhesin  
from Haemophilus parainfluenzae HP-28.

Lai CH; Bloomquist C; Liljemark WF

Department of Diagnostic School of Dentistry, University of

Minnesota,  
Minneapolis 55455.

Infect Immun Dec 1990, 58 (12) p3833-9, ISSN 0019-9567

Journal Code: G07

Contract/Grant No.: R37-DE04614

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/10 (Item 10 from file: 155)

07400795 90307795

Characterization of a maternal type VI collagen in  
Xenopus embryos  
suggests a role for collagen in gastrulation.

Otte AP; Roy D; Siemerink N; Koster CH; Hochstenbach F;  
Timmersmans A;

Durston AJ

Hubrecht Laboratory, Netherlands Institute for  
Developmental Biology,  
Utrecht.

J Cell Biol Jul 1990, 111 (1) p271-8, ISSN 0021-9525

Journal Code:

Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/11 (Item 11 from file: 155)

07349288 90256288

A proteolytic enzyme secreted by *Proteus mirabilis* degrades immunoglobulins of the immunoglobulin A1 (IgA1), IgA2, and IgG isotypes.

Loomes LM; Senior BW; Kerr MA

Department of Pathology, Dundee University Medical School, Ninewells Hospital, Scotland.

Infect Immun Jun 1990, 58 (6) p1979-85, ISSN 0019-9567

Journal Code: G07

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/12 (Item 12 from file: 155)

07345988 90252988

Adaptation of fluorescence polarization immunoassay to the assay of macromolecules.

Urios P; Cittanova N

Departement de Biochimie, U.F.R. Biomedicale des Saints-Peres, Paris, France.

Anal Biochem Mar 1990, 185 (2) p308-12, ISSN 0003-2697

Journal Code: 4NK

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/13 (Item 13 from file: 155)

07062848 89364848

Immunochemical studies of a murine polyreactive IgG2b autoantibody with rheumatoid factor activity.

Fernandez PA; Ternynck T; Avrameas S

Departement d'Immunologie, Institut Pasteur, Paris, France.

Mol Immunol Jun 1989, 26 (6) p539-49, ISSN 0161-5890

Journal Code:

NG1

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/14 (Item 14 from file: 155)

07025206 89327206

Physical, enzymatic, and contractile properties of brain myosin with anti-brain myosin Fab fragment bound on its tail.

Matsumura S; Ohmori K; Chiba T; Kumon A

Department of Biochemistry, Saga Medical School.

J Biochem (Tokyo) May 1989, 105 (5) p803-12, ISSN 0021-924X

Journal Code: HIF  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/15 (Item 15 from file: 155)

06965705 89267705

Purification of F(ab')<sub>2</sub> anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield.

dos Santos WC; D'Imperio Lima MR; Furtado GC; Colletto GM; Kipnis TL;

Dias da Silva W

Fundacao Ezequiel Dias, Universidade Federal de Minas Gerais, Brazil.

Toxicon 1989, 27 (3) p297-303, ISSN 0041-0101 Journal Code: VMT

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/16 (Item 16 from file: 155)

06947897 89249897

Sensitive enzyme immunoassay for human aldolase B.

Haimoto H; Kurobe N; Hosoda S; Kato K

Laboratory of Pathology, Aichi Cancer Center Research Institute, Nagoya, Japan.

Clin Chim Acta Apr 28 1989, 181 (1) p27-36, ISSN 0009-8981

Journal Code: DCC

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/17 (Item 17 from file: 155)

06891493 89193493

C3 binds covalently to the C gamma 3 domain of IgG immune aggregates

during complement activation by the alternative pathway.

Anton LC; Alcolea JM; Sanchez-Corral P; Marques G; Sanchez A; Vivanco F

Department of Immunology, Fundacion Jimenez Diaz, Madrid, Spain.

Biochem J Feb 1 1989, 257 (3) p831-8, ISSN 0264-6021

Journal Code:

9YD

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/18 (Item 18 from file: 155)

06766852 89068852

Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies

and their Fab fragments.

Polymers of the Rhinovirus Capsid Protein P2: Inactivation of

Merck Sharp and Dohme Research Laboratories, West Point,  
Pennsylvania

19486.

J Virol Jan 1989, 63 (1) p36-42, ISSN 0022-538X Journal

Code: KCV

Contract/Grant No.: AI24939

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/19 (Item 19 from file: 155)

06730765 89032765

Large scale production and purification of paraquat and  
desipramine

monoclonal antibodies and their Fab fragments.

Bowles M; Johnston SC; Schoof DD; Pentel PR; Pond SM

Department of Medicine, University of Queensland, Princess  
Alexandra

Hospital, Brisbane, Australia.

Int J Immunopharmacol 1988, 10 (5) p537-45, ISSN 0192-0561

Journal Code: GRI

Contract/Grant No.: ES03003

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/20 (Item 20 from file: 155)

06587708 88232708

Streptococcal protein G has affinity for both Fab- and  
Fc-fragments of  
human IgG.

Erntell M; Myhre EB; Sjobring U; Bjorck L

University of Lund, Department of Infectious Diseases,  
University

Hospital, Sweden.

Mol Immunol Feb 1988, 25 (2) p121-6, ISSN 0161-5890

Journal Code:

NG1

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/21 (Item 21 from file: 155)

06529459 88174459

Resistance of normal serum IgA and secretory IgA to  
bacterial IgA

proteases: evidence for the presence of enzyme-neutralizing  
antibodies in

both serum and secretory IgA, and also in serum IgG.

Kobayashi K; Fujiyama Y; Hagiwara K; Kondoh H

Department of Pediatrics, Yamaguchi University School of  
Medicine.

Microbiol Immunol 1987, 31 (11) p1097-106, ISSN 0305-5608

Journal Code: MX7

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/22 (Item 22 from file: 155)  
00495291 00140291  
Protein L. A novel bacterial cell wall protein with  
affinity for Ig L  
chains.  
Bjorck L  
Department of Medical Microbiology, University of Lund, Sweden.

J Immunol Feb 15 1988, 140 (4) p1194-7, ISSN 0022-1767  
Journal Code: IFB  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/22 (Item 23 from file: 155)  
00477156 00122156  
The heterogeneity of bovine IgG2--III. The ion-exchange  
heterogeneity of  
IgG2a is the result of VH-region variation.  
Butler JE; Borca MV; Mayermann H; Dillender M; Bielecka M  
University of Iowa Medical School, Department of Microbiology,  
Iowa City  
52242.  
Mol Immunol Dec 1987, 24 (12) p1317-26, ISSN 0161-5890  
Journal Code: NGI  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/24 (Item 24 from file: 155)  
00420469 00265469  
[Intramolecular mobility of human major  
histocompatibility complex  
protein. A spin-label study]

Унутримолекулярная подвижность белков главного  
комплекса  
гистосовместимости человека. Исследование методом спиновой метки.  
Mezlin RS; Pankratova EV; Kuliguckin VV; Arutunian AE;  
Timofeev VP  
Mol Biol (Mosk) Sep-Oct 1997, 21 (5) p1426-34, ISSN  
0026-0984  
Journal Code: NGX  
Languages: RUSSIAN Summary Languages: ENGLISH  
Document type: JOURNAL ARTICLE English Abstract

10/3/25 (Item 25 from file: 155)  
00317061 07291061  
Enzymatic fragmentation of an unusual human IgG2 (Kva) myeloma  
protein.  
Vogt RA; Michaelsen TE  
Scand J Immunol Jul 1927, 26 (1) p53-69, ISSN 0300-0475  
Journal Code: UGM  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

06014050 07100250

Binding to cell lines of IgG from patients with  
interstitial lung  
diseases.

Demail M; Baur Y

Clin Chim Acta Feb 27 1987, 163 (1) p87-95, ISSN 0008-8991

Journal Code: BCC

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/87 (Item 27 from file: 155)

06136774 87110774

Identification of immunoreactive monoclonal antibody  
fragments for  
improved immunoscintigraphy.

Mather GJ; Durbin M; Taylor-Papadimitriou J

J Immunol Methods Feb 11 1987, 95 (2) p255-64, ISSN  
0022-1759

Journal Code: IFE

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/86 (Item 28 from file: 155)

06050626 87030626

The molecular organization of the protein HC-IgA complex  
(HC-IgA).

Grubb A; Mendez E; Fernandez-Luna JL; Lopez O; Mihaesco E;  
Vaccaroni JP

J Biol Chem Oct 25 1986, 261 (30) p14213-20, ISSN 0021-9258

Journal Code: NIV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/86 (Item 29 from file: 155)

06056342 87030342

Comparative imaging and biodistribution studies with an  
anti-CEA  
monoclonal antibody and its F(ab)2 and Fab fragments in mice  
with colon  
carcinoma xenografts.

Andrew CM; Pico MV; Perkins AD; Baldwin RW

Eur J Nucl Med 1986, 12 (4) p168-75, ISSN 0240-6997

Journal Code:

ENC

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/80 (Item 30 from file: 155)

06055500 06055500

Preparation of F(ab)2 fragments from source IgG of various  
subclassess.

Lanczyi E

Methods Enzymol 1984, 121 p153-63, ISSN 0071-6070, Journal

Code: MVA  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/31 (Item 31 from file: 155)

05856756 86157756

Dermatitis herpetiformis: 'pH optimum' for the release of potentially antigen-binding IgA fragments from papillary dermis of uninvolved skin by peptic digestion.

Egelrud T; Back O

Arch Dermatol Res 1985, 278 (1) p44-8, ISSN 0340-3696

Journal Code: 6X7

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/32 (Item 32 from file: 155)

05600021 85296021

Preparation and biologic characterization of fragments containing dimeric and monomeric C gamma 2 domain of rabbit IgG.

Utsuni S; Okada M; Uchida K; Amano T

Mol Immunol Jul 1985, 22 (7) p811-9, ISSN 0161-5890

Journal Code:

NS1

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/33 (Item 33 from file: 155)

05543152 85159152

Dermatitis herpetiformis: biochemical properties of the

granular deposits of IgA in papillary dermis. Characterization of SDS-soluble IgA-like material and potentially antigen-binding IgA fragments released by pepsin.

Egelrud T; Back O

J Invest Dermatol Apr 1985, 84 (4) p239-45, ISSN 0022-202X

Journal Code: IHZ

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/34 (Item 34 from file: 155)

05515506 85131506

One-step procedure for the rapid isolation of mouse monoclonal antibodies and their antigen binding fragments by fast protein liquid chromatography on a mono Q anion-exchange column.

Clezardin P; McGregor JL; Manach M; Boukerche H; Dechavanne M

J Chromatogr Jan 25 1985, 319 (1) p67-77, ISSN 0021-9673

Journal Code: HZF

Document type: JOURNAL ARTICLE

10/3/35 (Item 35 from file: 155)  
05457007 85073807

Immunoglobulin G1 Fc in colostral whey.

Nielsen K; Stiller J; Sowa B

Can J Comp Med Oct 1984, 48 (4) p410-3, ISSN 0008-4050

Journal Code: CIO

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/36 (Item 36 from file: 155)  
05451366 85067366

[Isolation of the Fab fragment from immune sera]

Poluchavane na Fab-fragment ot imunni serum.

Chenchev I; Vasileva L

Vet Med Nauki 1984, 21 (7-8) p44-8, ISSN 0324-1068

Journal Code:

XCE

Languages: BULGARIAN Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE English Abstract

10/3/37 (Item 37 from file: 155)  
05431279 85047279

Interaction of porcine immunoglobulin M with protein A of  
Staphylococcus  
aureus.

Gentile TC; Dierks SE; Watt RM

Biochim Biophys Acta Nov 23 1984, 791 (1) p102-11, ISSN

0006-3602

Journal Code: AOW

Contract/Grant No.: BRS-E-195J; HL29340

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/38 (Item 38 from file: 155)  
05374007 84298007

[Proteolysis of horse blood serum proteins at various stages of  
antitoxic

sera production by the Diaferm-3 method]

O proteolize belkov syvorotki krovi loshadi na razlichnykh  
stadiiakh

poluchenia antitoksicheskikh syvorotok po metodu "Diaferm-3".

Grechushkina-Sukhorukova NA; Tel'bukh VP; Stepanov VM

Prikl Biokhim Mikrobiol Jul-Aug 1984, 20 (4) p528-33, ISSN

0555-1099

Journal Code: PMS

Languages: RUSSIAN Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE English Abstract

10/3/39 (Item 39 from file: 155)  
05317147 84241147

Purification and some properties of streptococcal protein

IgG-binding reagent.  
Bjorck L; Kronvali G  
J Immunol Aug 1984, 133 (2) p969-74, ISSN 0022-1767  
Journal Code:  
IFE  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/40 (Item 40 from file: 155)  
05139023 84063023  
Optimal conditions for the preparation of Fab and F(ab')<sub>2</sub> fragments from monoclonal IgG of different rat IgG subclasses.  
Rousseaux J; Rousseaux-Prevest R; Bazin H  
J Immunol Methods Nov 11 1983, 64 (1-2) p141-6, ISSN 0022-1759  
Journal Code: IFE  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/41 (Item 41 from file: 155)  
05129397 84053397  
Disulfide linking of albumin to the hinge region of immunoglobulin G in normal human serum.  
Mohammad SF; Sharma N; Woodward SC  
Biochim Biophys Acta Nov 28 1983, 749 (1) p47-51, ISSN 0006-3002  
Journal Code: A0W  
Contract/Grant No.: HL-25004; HL-25006  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/42 (Item 42 from file: 155)  
04954594 83187594  
Simplified preparation of rabbit Fab fragments.  
Coulter A; Harris R  
J Immunol Methods Apr 29 1983, 59 (2) p199-203, ISSN 0022-1759  
Journal Code: IFE  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/43 (Item 43 from file: 155)  
04829514 83062514  
An unusual papain cleavage of a human IgG1 (lambda) myeloma protein (Mot).  
Kojima M; Odani S; Ono T  
Mol Immunol Sep 1982, 19 (9) p1095-103, ISSN 0161-5890  
Journal Code: M01  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/44 (Item 44 from file: 155)

04704942 82247942

Antibodies to RNA from autoimmune NZB/NZW mice recognize a similar

antigenic determinant and show a large idiosyncrasy.

Eilat D; Hochberg M; Fischel R; Laskov R

Proc Natl Acad Sci U S A Jun 1982, 79 (12) p3818-22, ISSN

0027-8424

Journal Code: PV3

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/45 (Item 45 from file: 155)

04569229 82112229

Enzymatic and immunochemical properties of lysozyme--restriction of recognition of lysozyme antigenic determinants in pigs.

Habeeb AF

Arch Biochem Biophys Dec 1981, 212 (2) p618-28, ISSN

0003-9861

Journal Code: 6SK

Contract/Grant No.: AI-14791

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/46 (Item 46 from file: 155)

04503815 82046815

A comparison of the actions of trypsin and pepsin on porcine

immunoglobulin M and their effects on biological activity.

Beale D; Fazakerley JK

Biochim Biophys Acta Sep 29 1981, 670 (2) p230-5, ISSN

0006-3002

Journal Code: A0W

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/47 (Item 47 from file: 155)

04382697 81210697

Site of alkaline phosphatase attachment in alkaline

phosphatase-immunoglobulin G complexes.

Crofton PM

Clin Chim Acta Apr 27 1981, 112 (1) p33-42, ISSN 0009-8981

Journal Code: DCC

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/48 (Item 48 from file: 155)

04305566 81133566

The action of pepsin on porcine immunoglobulin M and its effect on

biological activity.

Biochem J Oct 1 1980, 191 (1) p183-91, ISSN 0006-2936  
Journal Code: 9Y0  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/49 (Item 49 from file: 155)  
04240436 81068436  
Immunoglobulin produced by guinea-pig leukaemic B lymphocytes:  
its source  
and use as a monitor of tumour load.  
Stevenson FK; Morris D; Stevenson GT  
Immunology Oct 1980, 41 (2) p313-21, ISSN 0019-2805  
Journal Code:  
GH7  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/50 (Item 50 from file: 155)  
04187392 81015392  
Kinetics of the different susceptibilities of the  
four human  
immunoglobulin G subclasses to proteolysis by human lysosomal  
elastase.  
Baici A; Knopfel M; Fehr K; Skvaril F; Boni A  
Scand J Immunol 1980, 12 (1) p41-50, ISSN 0300-9675  
Journal Code:  
UCW  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/51 (Item 51 from file: 155)  
03909920 80020920

The crystallizable human myeloma protein Dob has a hinge-region  
deletion.  
Steiner LA; Lopes AD  
Biochemistry Sep 18 1979, 18 (19) p4054-67, ISSN 0006-2960  
Journal Code: A06  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/52 (Item 52 from file: 155)  
03905762 80016762  
Isolation of enzymatically derived fragments of porcine  
IgG and an  
examination of their reactivity against staphylococcal protein A.  
Endresen C  
Acta Pathol Microbiol Scand [C] Jun 1979, 87C (3)  
p177-83, ISSN  
0304-1328 Journal Code: 103  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/53 (Item 53 from file: 155)

03807467 79184467

Purification and characterization of rabbit anti-mouse renin specific Fab fragments.

Lykkegaard S

Acta Pathol Microbiol Scand [C] Apr 1979, 87C (2) p91-7, ISSN

0304-1328 Journal Code: 103

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/54 (Item 54 from file: 155)

03665153 79042153

An IgG2a-producing variant of an IgG2b-producing mouse myeloma cell line.

Structural studies on the Fc region of parent and variant heavy chains.

Francus T; Birshstein BK

Biochemistry Oct 3 1978, 17 (20) p4324-31, ISSN 0006-2960

Journal Code: A06

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/55 (Item 55 from file: 155)

03641119 79018119

Isolation of enzymatically derived fragments of guinea pig IgG and an examination of their reactivity against Staphylococcal protein A.

Endresen C; Grov A

Acta Pathol Microbiol Scand [C] Aug 1978, 86C (4) p193-8, ISSN

0304-1328 Journal Code: 103

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/56 (Item 56 from file: 155)

03579573 78213573

The immunoglobulin nature of nephritic factor (NeF).

Scott DM; Amos N; Sissons JG; Lachmann PJ; Peters DK

Clin Exp Immunol Apr 1978, 32 (1) p12-24, ISSN 0009-9104

Journal Code: DD7

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/57 (Item 57 from file: 155)

03237866 77139866

Enzymatic fragmentation of human IgA F(abc)'2: a new peptic fragment.

Rivat C; Bourguignon J; Fontaine M; Repartz C

Immunochemistry Jan 1977, 14 (1) p69-73, ISSN 0019-2791

Journal Code: GM2

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/58 (Item 58 from file: 155)

03050489 76231489

Fb'2, a new peptic fragment of human immunoglobulin G.

Parr DM; Connell GE; Kells DI; Hofmann T

Biochem J Apr 1 1976, 155 (1) p31-6, ISSN 0006-2936

Journal Code:

9YD

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/59 (Item 59 from file: 155)

03011396 76192396

Biologic activities of rabbit immunoglobulin G in relation to domains of

the Fc region.

Ovary Z; Saluk PH; Quijada L; Lamm ME

J Immunol May 1976, 116 (5) p1265-71, ISSN 0022-1767

Journal Code:

IFB

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/60 (Item 60 from file: 155)

02741551 75148551

[Study of the products of pepsin digestion of dimeric forms of human

serum IgA]

Etude des produits de digestion par la pepsine des formes dimeriques des

IgA seriques humaines

Rivat C; Bourguignon J; Fontaine M; Repartz C

C R Acad Sci Hebd Seances Acad Sci D Oct 14 1974, 279 (16) p1405-7,

ISSN 0567-655X Journal Code: C9C

Languages: FRENCH

Document type: JOURNAL ARTICLE

10/3/61 (Item 61 from file: 155)

02727375 75134375

The isolation and characterization of the V-H domain from rabbit heavy

chains of different a locus allotype.

Mole LE; Geier MD; Koshland ME

J Immunol May 1975, 114 (5) p1442-8, ISSN 0022-1767

Journal Code:

IFB

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/62 (Item 62 from file: 155)

02621414 75028414

Fragmentation and reduction of porcine 19 S immunoglobulin M.

FEBS Lett Aug 25 1974, 44 (2) p229-40, ISSN 0014-5793  
Journal Code: EMBL  
Language: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/63 (Item 63 from file: 155)  
02452447 74171447  
Papain digestion of pig IgM.  
Zikan J; Miller I  
Immunochimistry Mar 1974, 11 (2) p115-8, ISSN 0019-2701  
Journal Code: CMB  
Language: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/64 (Item 64 from file: 155)  
02404449 74122449  
MU-chain disease in an African patient.  
Berkhove J; Seligsman M; Mikhaess G; Clauvel JP; Banch F;  
Brouet JC;  
Zouvy F; Martine J; Clerc M  
Blood Apr 1974, 43 (4) p405-02, ISSN 0006-4971 Journal  
Code: ABB  
Language: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/65 (Item 65 from file: 155)  
02057359 74075359  
Characterization of subclass-related F(ab)2, Fab-a and Fab  
fragments  
obtained by short papain digestion of human IgG myeloma  
proteins.  
Michaelsson TE; Natvig JB

Scand J Immunol 1973, 2 (3) p209-212, ISSN 0300-9607  
Journal Code:  
LBN  
Language: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/66 (Item 66 from file: 155)  
02002005 74010005  
Specific heterologous enhancement of immune responses. V.  
Isolation of a  
soluble enhancing factor from supernatants of specifically  
stimulated and  
allogeneically induced lymphoid cells.  
Rubin AD; MacDonald AD; Coons RM  
J Immunol Nov 1973, 111 (5) p1314-25, ISSN 0022-1767  
Journal Code:  
IFB  
Language: ENGLISH  
Document type: JOURNAL ARTICLE

10/3/67 (Item 67 from file: 155)  
02037071 74010071

Three new fragments, Fab' 2, Fab' 2', and Fab'-a, obtained by papain proteolysis of normal human IgG.

Michaelson TE; Natvig JB

Scand J Immunol 1972, 1 (3) p355-58, ISSN 0303-9007

Journal Code:

UCH

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/68 (Item 66 from file: 155)

02054924 73033024

Atypical immunoglobulins associated with spontaneous lymphomas in an inbred strain of mice.

Schreckenbach AE; Bailey PC

J Natl Cancer Inst Oct 1972, 49 (4) p1027-37, ISSN

0027-0874

Journal Code: J9J

Languages: ENGLISH

Document type: JOURNAL ARTICLE

10/3/69 (Item 1 from file: 55)

0002678 BIOBIO Number: 91024678

CRYSTALLIZATION AND PRELIMINARY X-RAY DIFFRACTION STUDIES OF THE FAB

FRAGMENT OF A NEUTRALIZING MONOCLONAL ANTIBODY DIRECTED AGAINST HUMAN

RHINOVIRUS SEROTYPE 2

TORNO J; FITA I; KANZLER O; BLAAS D

DEP. D'ENGINYERIA QUIMICA, ESCOLA TECNICA SUPERIOR D'ENGINYERS INDUSTRIALS DE BARCELONA, UNIVERSITAT POLITECNICA DE CATALUNYA,

DIAGONAL

647, E-28021 BARCELONA, SPAIN.

J BIOL CHEM 265 (28), 1990, 16709-16700. CODEN: JBCHA

Full Journal Title: Journal of Biological Chemistry

Languages: ENGLISH

10/3/70 (Item 2 from file: 55)

7163722 BIOBIO Number: 00005465

UNIQUE FEATURES OF MONOCLONAL IgG2B IN THE CLEAVAGE REACTION WITH PEPAIN

OHMI H; TSUTSUMI K; HATOHASHI H; INOUE H; TANABE S; ODA T

DEP. ORTHOPEDIC SURG., OKAYAMA UNIV. MED. SCH., CANCER INST., OKAYAMA

UNIV. MED. SCH., OKAYAMA 700, JAPAN.

ACTA MED OKAYAMA 43 (2), 1990, 135-142. CODEN: AMOKA

Full Journal Title: Acta Medica Okayama

Languages: ENGLISH

10/3/71 (Item 3 from file: 55)

0504005 BIOBIO Number: 05104616

PROTEIN L A NOVEL BACTERIAL CELL WALL PROTEIN WITH AFFINITY FOR

CHAINS

BJORCK L

DEP. MED. MICROBIOL., UNIV. LUND. SOLVEGATAN 23, S-223 62 LUND,  
SWEDEN.

J IMMUNOL 140 (4). 1988. 1194-1197. CODEN: JOINA

Full Journal Title: Journal of Immunology

Language: ENGLISH

10/3/72 (Item 4 from file: 55)

5761983 BIOSIS Number: 83024293

THE MOLECULAR ORGANIZATION OF THE PROTEIN HC-IMMUNOGLOBULIN A  
COMPLEX

GRUBB A; MENDEZ E; FERNANDEZ-LUNA J L; LOPEZ C; MIHAESCO E;  
VAERMAN J-P

DEP. CLINICAL CHEM., UNIV. LUND, MALMO GENERAL HOSP., S-214 01  
MALMO,  
SWED.

J BIOL CHEM 261 (30). 1986. 14312-14320. CODEN: JBCHA

Full Journal Title: Journal of Biological Chemistry

Language: ENGLISH

10/3/73 (Item 5 from file: 55)

5286014 BIOSIS Number: 81053321

DERMATITIS HERPETIFORMIS PH OPTIMUM FOR THE RELEASE OF  
POTENTIALLY

ANTIGEN-BINDING IMMUNOGLOBULIN A FRAGMENTS FROM PAPILLARY DERMIS  
OF

UNINVOLVED SKIN BY PEPTIDE DIGESTION

EGELRUD T; BAECK O

DEP. DERMATOL., UNIV. HOSP., S-901 85 UMEA, SWEDEN.

ARCH DERMATOL RES 278 (1). 1985. 44-48. CODEN: ADRE

Full Journal Title: Archives of Dermatological Research

Language: ENGLISH

10/3/74 (Item 6 from file: 55)

4886048 BIOSIS Number: 80013359

DERMATITIS HERPETIFORMIS BIOCHEMICAL PROPERTIES OF THE GRANULAR  
DEPOSITS

OF IMMUNOGLOBULIN A IN PAPILLARY DERMIS CHARACTERIZATION OF  
SODIUM DODECYL

SULFATE-SOLUBLE IMMUNOGLOBULIN A-LIKE MATERIAL AND POTENTIALLY  
ANTIGEN-BINDING IMMUNOGLOBULIN A FRAGMENTS RELEASED BY PEPSIN

EGELRUD T; BAECK O

DEPARTMENT OF DERMATOLOGY, UNIVERSITY HOSPITAL, S-901 85 UMEA,  
SWEDEN.

J INVEST DERMATOL 84 (4). 1985. 239-245. CODEN: JIDEA

Full Journal Title: Journal of Investigative Dermatology

Language: ENGLISH

10/3/75 (Item 7 from file: 55)

4779886 BIOSIS Number: 79022201

PURIFICATION AND SOME PROPERTIES OF STREPTOCOCCAL PROTEIN G A  
NOVEL

Language: ENGLISH

AT E1 V1 X0 DT3059488  
CONNECT

Enter terminal type or "M" for menu - KSR

PLEASE ENTER HOST PORT ID:x

LOGINID:di26rbs

PASSWORD:HHHHHHHH^H^H^H^H^H^H^HIIIIII^H^H^H^H^H^H^H

##### ^H^H^H^H^H^H^H^H^Hdude

\*\*\*\*\*  
 PASSWORD:\*\*\*\*\*

```
#####^H^H^H^H^H^H^H^H^H^H
```

TERMINAL (ENTER 1, 2, 3, 4, OR ?):3

\* \* \* \* \*

✠

```

*      Welcome to MESSENGER at USPTO      *

```

\*\*\*



\*\*\*\*\*  
FILE 'USPAT' ENTERED AT 11:34:27 ON 04 FEB 93

\*\*\*\*\*  
\* WELCOME TO THE \*  
\* U. S. PATENT TEXT FILE \*  
\*\*\*\*\*

=> s venom or antivenin  
682 VENOM  
4 ANTIVENIN  
L1 682 VENOM OR ANTIVENIN

=> s fab or fab2 or f(ab) or f(ab)2  
MISSING OPERATOR 'OR F(AB'

=> s fab or fab2 or f(ab) or f(ab)2  
MISSING OPERATOR 'OR F(AB'  
YOU HAVE RECEIVED THIS ERROR MESSAGE 2 CONSECUTIVE TIMES  
The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.  
IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK  
=> s fab or fab2 or f(ab) or f(ab)2  
MISSING OPERATOR 'OR F(AB'

=> s fab or fab2  
2470 FAB

@ FAB2  
L2 2470 FAB OR FAB2

=> s 12 and 11  
L3 39 L2 AND L1

=> t 13 cit ab 1-39

1. 5,180,820, Jan. 19, 1993, Brain-derived neurotrophic factor;  
Yves-Alain Barde, et al., 536/23.51; 435/69.1, 69.3, 172.3,  
320.1;  
530/399, 412 [IMAGE AVAILABLE]

US PAT NO: 5,180,820 [IMAGE AVAILABLE] L3: 1 of  
39

ABSTRACT:  
The present invention relates to nucleic acid sequences encoding  
brain  
derived neurotrophic factor (BDNF), as well as BDNF protein  
produced in

and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the ability to generate sufficient quantities of substantially pure BDNF for clinical use. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient isozyme. Further, by permitting a comparison of the nucleic acid sequences of BDNF and NSF, the present invention provides for the identification of homologous regions of nucleic acid sequence between BDNF and NSF, thereby defining a BDNF/NSF gene family; the invention provides a method for identifying and isolating additional members of this gene family.

2. 5,175,273, Dec. 29, 1992, Nucleic acid intercalating agents; Norbert W. Bischofberger, et al., 526/27, 1.1, 18.7, 22, 23, 28, 29  
IMAGE  
AVAILABLE

US PAT NO: 5,175,273 [IMAGE AVAILABLE] L3: 2 of 39

ABSTRACT:  
Pyridinone or pyrimidinone nucleoside bases containing fused aromatic polycyclic rings are provided. These polycyclic nucleosides are incorporated into oligonucleotides and hybridized to complementary nucleic acid. Fluorescence spectroscopy and thermal denaturation profiles provided evidence that the polycyclic base is intercalated into the resulting duplex. The fused polycyclic ring systems optionally are substituted with reactive species which inactivate complementary nucleic acids. The oligonucleotides of this invention are useful as improved probes, diagnostic reagents, or for cleaving or derivatizing predetermined domains within nucleic acids.

2. 5,171,864, Dec. 15, 1992, 2i-(5-hydroxy-2-(5H)-2-one-4-furyl)methyl-

Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl- $\alpha,\omega$ -dialkanoic acid amides as  
anti-inflammatory  
agents; Gary C. M. Lee, 549/222, 318 [IMAGE AVAILABLE]

US PAT NO: 5,171,864 [IMAGE AVAILABLE]  
39

L3: 3 of

ABSTRACT:

Compounds of the formula  $\text{R.sub.1}$  in which R.sub.1 independently is H or alkyl of 1 to 20 carbons, CO--R.sub.2, CO--O--R.sub.2, CO--NH--R.sub.2, or PO(OR.sub.2).sub.2 or PO(OR.sub.2)R.sub.2, where R.sub.2 independently is H, alkyl of 1 to 20 carbons, phenyl, or lower alkyl substituted phenyl or halogen substituted phenyl; A is (CH.sub.2).sub.n where n ranges between 5 to 30, or A is a divalent branch chained alkyl radical, or cycloalkyl radical, having a total of 5 to 30 carbons, and X is O or NH, have anti-inflammatory activity.

4. 5,169,963, Dec. 8, 1992,  
Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)alkylmethyl-  
 $\alpha,\omega$  alkanedioates and N,N-bis-(5-hydroxy-2(5H)-2-oxo-4-  
furyl)alkylmethyl- $\alpha,\omega$ -dialkanoic acid amides as  
anti-inflammatory  
agents; Gary C. M. Lee, 549/222, 318 [IMAGE AVAILABLE]

US PAT NO: 5,159,963 [IMAGE AVAILABLE]

L3: 4 of

39

ABSTRACT:

Compounds of the formula  $\text{R.sub.1}$  in which R.sub.1 independently is H or alkyl of 1 to 29 carbons, CO-R.sub.2, CO-O-R.sub.2, CO-NH-R.sub.2, or PO(OR.sub.2).sub.2 or PO(OR.sub.2)R.sub.2, where R.sub.2 independently is H, alkyl of 1 to 20 carbons, phenyl, or lower alkyl substituted phenyl or halogen substituted phenyl; A is (CH.sub.2).sub.n where n ranges between 0 to 30, or A is a divalent branch chained alkyl radical, or cycloalkyl radical, having a total of 3 to 30 carbons; R.sub.3 independently is an alkyl group having 4 to 20 carbons, and X is O or NH, have anti-inflammatory activity.

5. 5,169,933, Dec. 8, 1992, Covalently-linked complexes and

enhanced cytotoxicity and imaging; David C. Anderson, et al.,  
530/391.3;  
424/1.1, 9, 85.91; 530/306, 307, 308, 313, 323, 324, 325, 326,  
327, 328,  
329, 330, 351, 377, 391.1, 391.5, 391.7, 391.9, 395, 399, 403,  
408, 409,  
410 [IMAGE AVAILABLE]

US PAT NO: 5,169,933 [IMAGE AVAILABLE]  
39

L3: 5 of

ABSTRACT:

Covalently-linked complexes (CLCs) for targeting a defined population of cells, comprising a targeting protein; a cytotoxic agent; and an enhancing moiety, wherein the enhancing moiety is capable of promoting CLC-target cell interaction are disclosed. Methods for using the claimed CLCs to obtain enhanced in vivo cytotoxicity and enhanced in vivo imaging are also described.

6. 5,162,504, Nov. 10, 1992, Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients; Julius S. Horoszewicz, 530/388.2; 435/7.23, 70.21, 240.27;  
530/388.8 [IMAGE AVAILABLE]

US PAT NO: 5,162,504 [IMAGE AVAILABLE]

L3: 6 of

39

ABSTRACT:

Monoclonal antibodies to prostatic cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies show specificity for a non-soluble, membrane associated, organ specific antigenic determinant limited in its distribution to normal and neoplastic, human prostate epithelial cells. The monoclonal antibodies, specifically 7E11-C5 monoclonal antibodies, may be suitable for diagnostic uses.

7. 5,159,005, Oct. 27, 1992, 2-anilino phenylacetic acid derivatives as inhibitors of PLA.sub.2 and lipoxxygenase; Amedeo A. Failli, et al.,  
548/310.1, 341.1, 342.5 [IMAGE AVAILABLE]

US PAT NO:

5,159,005 [IMAGE AVAILABLE]

L3: 7 of

ABSTRACT:

There are disclosed compounds of the formula ##STR1## wherein R is hydroxy, lower alkoxy or lower alkoxyamino; R.sup.1 is hydrogen or A(CH.sub.2).sub.n O--; R.sup.2 is hydrogen or A(CH.sub.2).sub.n O--, with the proviso that one of R.sup.1 and R.sup.2 is hydrogen; n is 1-2; A is phenoxyethyl, phenoxyphenyl or a group having the formula ##STR2## R.sup.3 is hydrogen, lower alkyl or phenyl; R.sup.4 is hydrogen or lower alkyl; or R.sup.3 and R.sup.4 taken together form a benzene ring; R.sup.5 is hydrogen or lower alkyl; R.sup.6 is hydrogen, halo or lower alkyl; and the pharmacologically acceptable salts thereof, and their use in the treatment of inflammatory conditions, such as rheumatoid arthritis, ulcerative colitis, psoriasis and other immediate hypersensitivity reactions; in the treatment of leukotriene-mediated naso-bronchial obstructive air-passageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like; and as gastric cytoprotective agents.

8. 5,156,840, Oct. 20, 1992, Amine-containing porphyrin derivatives; John W. F. Goers, et al., 424/85.91; 514/410 [IMAGE AVAILABLE]

US PAT NO: 5,156,840 [IMAGE AVAILABLE] L3: 8 of 39

ABSTRACT:

The invention relates to amine-containing porphyrin derivatives. The porphyrins can be used as photosensitizers which are useful as therapeutic agents. Also described are methods for preparing conjugates in which a porphyrin derivative is covalently attached to an antibody or antibody fragment. In vivo therapeutic methods utilizing the conjugates are also desired.

9. 5,135,736, Aug. 4, 1992, Covalently-linked complexes and

enhanced cytotoxicity and imaging; David C. Anderson, et al.,  
424/1.1, 9,  
85.91, 94.3; 435/188; 514/8, 12, 21; 530/387.1, 388.15, 388.8,  
389.7,  
391.3, 391.7, 395 [IMAGE AVAILABLE]

US PAT NO: 5,135,736 [IMAGE AVAILABLE]

L3: 9 of

39

ABSTRACT:

Covalently-linked complexes (CLOs) for targeting a defined population of cells, comprising a targeting protein or peptide; a cytotoxic agent; and an enhancing moiety, wherein the enhancing moiety is capable of promoting CLO-membrane interaction are disclosed. Methods for using the claimed CLOs to obtain enhanced in vivo cytotoxicity and enhanced in vivo imaging are also described.

10. 5,120,537, Jun. 9, 1992, Factor Xa based anticoagulant compositions;  
Charles T. Esmon, et al., 424/94.64; 435/69.6, 212, 226; 514/2,  
12, 21;  
530/381 [IMAGE AVAILABLE]

US PAT NO: 5,120,537 [IMAGE AVAILABLE]

L3: 10 of

39

ABSTRACT:

An anticoagulant composition containing an effective amount of factor Xa having the active serine site inactivated that functions rapidly and effectively in vivo to suppress coagulation. In a preferred embodiment, Factor Xa, a serine esterase that forms a complex with Factor Va, Ca<sup>++</sup>, and phospholipid to catalyze prothrombin activation, is first inactivated with an active site inhibitor, such as dansyl-gly-arg-chloromethyl ketone, to form inactivated factor Xa. In another embodiment, Factor Xa is expressed from a gene sequence wherein the portion encoding the active serine region is modified. The inactivated protein retains the ability to bind to endogenous factor Va in vivo, and has a half-life of approximately ten hours. Administration of inactive factor Xa to the

release of a leaving group; in the formation of a leaving group.  
Xa-Va  
complexes in vivo, thereby inhibiting coagulation.

11. 5,112,739, May 12, 1992, Enzyme controlled release system;  
Frank A.  
Meneghini, et al., 435/14, 4, 18, 19, 21, 24, 183; 436/546 [IMAGE

AVAILABLE]

US PAT NO: 5,112,739 [IMAGE AVAILABLE] L3: 11 of  
39

ABSTRACT:

This invention relates to an enzyme-controlled release method for  
the

release of a leaving group comprising:

contacting a compound represented by the formula ##STR1##  
wherein R,

R.sub.1, R.sub.2 and R.sub.3 each independently is hydrogen, a  
substituent affecting the mobility or reactivity of the compound  
or a

substituent including a biologically active group;

X is leaving group;

Z is an enzyme substrate moiety;

--CR.sub.2 R.sub.3 X is either ortho or para to the --O--Z  
moiety;

with an active capable of cleaving said enzyme substrate moiety Z  
from

said compound;

whereby said leaving group X is released from said compound.

12. 5,086,002, Feb. 4, 1992, Erythrocyte agglutination assay;

Carmel J.

Hillyard, et al., 436/540; 422/61; 435/7.25; 436/501, 519;  
530/387.3,  
388.7, 389.1, 866 [IMAGE AVAILABLE]

US PAT NO: 5,086,002 [IMAGE AVAILABLE] L3: 12 of  
39

ABSTRACT:

In a novel, erythrocyte agglutination assay, the agglutination  
reagent

comprises at least one erythrocyte binding molecule coupled to at  
least

one specific analyte binding molecule wherein the erythrocyte  
binding

molecule does not cause agglutination when incubated with  
erythrocytes in

the absence of analyte (in the case of a direct assay) or analyte  
binding

reagent (in the case of an indirect assay). Preferably, the  
erythrocytes

blood sample is assayed. Mixtures of conjugates and conjugates of analyte analogues with erythrocyte binding molecules may also be used as agglutination reagents. The reagents and their use in direct or indirect assays is disclosed.

13. 5,081,261, Jan. 14, 1992, 4-(1-hydroxy-2-N-substituted sulfonamido) ethyl-5-hydroxy-2(5H)-furanones and 4-(N-substituted sulfonamido)-2-ethenyl-5-hydroxy-2(5H)-furanones as anti-inflammatory agents; Gary C. M. Lee, 549/222; 544/229, 337, 379, 383; 549/214, 313, 318 [IMAGE AVAILABLE]

US PAT NO: 5,081,261 [IMAGE AVAILABLE] L3: 13 of 39

#### ABSTRACT:

Compounds of Formula 1, and of Formula 2, ##STR1## in which R.sub.1 is H or alkyl of 1 to 20 carbons, CO--R.sub.1.sup.\* CO--O--R.sub.1.sup.\* CO--NH--R.sub.1.sup.\* or PO(OR.sub.1.sup.\*).sub.2 or PO(OR.sub.1.sup.\*)R.sub.1.sup.\* where R.sub.1.sup.\* independently is H, alkyl of 1 to 20 carbons, phenyl, or substituted phenyl; R.sub.2 is H, alkyl of 1 to 20 carbons, or R.sub.2 and Y jointly represent a heterocycle which incorporates the sulfonamide nitrogen in the

ring as a heteroatom; R.sub.3 is H or alkyl of 1 to 20 carbons; X is H, R.sub.4, CO--R.sub.4, CO--O--R.sub.4, CO--NH--R.sub.4, CO--N--(R.sub.4).sub.2, PO(OR.sub.4).sub.2 or PO(OR.sub.4)R.sub.4, and R.sub.4 independently is H, phenyl, substituted phenyl, alkyl of 1 to 20 carbons or is alkyl of 1 to 20 carbons substituted with a hydroxyl, alkoxy, substituted amino, thioalkoxy, with a O--COR.sub.4.sup.\* group or with a COR.sub.4.sup.\* group where R.sub.4.sup.\* is H, lower alkyl, OH, OR.sub.4.sup.\* ^\_, NH.sub.2, NHR.sub.4.sup.\* ^\_ or N(R.sub.4.sup.\* ^\_).sub.2 group where R.sub.4.sup.\* ^\_ independently is H or lower alkyl, with the proviso that when X is CO--O--R.sub.4 or is CO--NH--R.sub.4 then R.sub.4 is not

to 20  
 carbons, or is alkyl of 1 to 20 carbons substituted with a hydroxyl, alkoxy, substituted amino, thioalkoxy, O--PO(OR.sub.5).sub.2, O--PO(OR.sub.5)R.sub.5, O--SO.sub.3 H, O--SO.sub.2 R.sub.5, O--COR.sub.5, or COR.sub.5 group where R.sub.5 is H, lower alkyl, OH, OR.sub.5.sup.\*, NH.sub.2, NHR.sub.5.sup.\* or N(R.sub.5.sup.\*).sub.2 group where R.sub.5.sup.\* is lower alkyl, or R.sub.2 and Y jointly represent a heterocycle which incorporates the sulfonamide nitrogen in the ring as a heteroatom, with the proviso that when Y is an alkyl substituted with O--PO(OR.sub.5).sub.2 or with O--PO(OR.sub.5)R.sub.5 then R.sub.5 is not OH, are disclosed. The compounds possess anti-inflammatory activity.

14. 5,671,835, Dec. 10, 1991, Ribonucleotide reductase inhibitors; Yvan Guindon, et al., 514/13, 15, 17, 18, 19; 530/326, 327, 328, 329 [IMAGE AVAILABLE]

US PAT NO: 5,671,835 [IMAGE AVAILABLE] L3: 14 of 39

# ABSTRACT:

Disclosed herein are peptides of the formula

Y--R.sub.1 --R.sub.2 --R.sub.3 --R.sub.4 --R.sub.5 --R.sub.6 --Z

wherein R.sub.1 to R.sub.5 are designated amino acid residues; R.sub.6 is Phe, homoPhe or an amino acid residue derived from 2-amino-3-cyclohexylpropionic acid, 2-amino-3-(4-(lower alkoxy)phenyl)propionic acid or 2-amino-3-(4-halophenyl)propionic acid; Y is Phe, desamino-Phe, (lower alkanoyl)-Phe, p-haloPhe, Tyr, desamino-Tyr or (lower alkanoyl)-Tyr, or Y is the decapeptide radical W--Val--R.sub.7 --Ser--R.sub.8 --R.sub.9 --Thr--Glu--R.sub.10 --Ser--Phe wherein W is hydrogen or lower alkanoyl and R.sub.7 to R.sub.10 are designated amino acids residues, or Y is a fragment of the decapeptide radical wherein from one to nine of the amino acid residues (i.e. Val to Ser) may be deleted serially from the amino terminus of the decapeptide radical; and

The peptides inhibit mammalian ribonucleotide reductase and are indicated for preventing or ameliorating abnormal cell proliferation.

15. 5,066,789, Nov. 19, 1991, Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages; Ananthachari Srinivasan, et al., 530/391.5, 363, 391.9 [IMAGE AVAILABLE]

US PAT NO: 5,066,789 [IMAGE AVAILABLE] L3: 15 of 39

ABSTRACT:  
Targeting substance-diagnostic/therapeutic agent conjugates joined by stabilized Schiff base or hydrazone linkages are disclosed. In addition, slow release carrier-drug pharmaceuticals are described. The diagnostic and therapeutic conjugates and pharmaceuticals of the present invention provide certain advantages relating to in vivo administration, including controlled release of the active agent at a target site.

16. 5,066,671, Nov. 19, 1991, Ellagic acid derivatives as phospholipase A.sub.2 inhibitors; Craig E. Caufield, 514/453 [IMAGE AVAILABLE]

US PAT NO: 5,066,671 [IMAGE AVAILABLE] L3: 16 of

39

ABSTRACT:  
There are disclosed a method for the treatment or prevention of immunoinflammatory conditions by administering to a mammal an effective amount of a compound having the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are each, independently, hydrogen, alkyl, aralkyl, aryl, or ##STR2## X is alkyl, aryl, or -NR.sup.5 R.sup.6 ; R.sup.5 and R.sup.6 are each independently hydrogen, alkyl, or aryl; aryl is ##STR3## where the dotted line represents an optional double bond; R.sup.7, and R.sup.8 and R.sup.9 are each, independently, hydrogen, alkyl, hydroxy, alkoxy, carbalkoxy, halo, nitro, amino, cyano, trifluoromethyl, or a carboxylic acid; n=1-3;

17. 5,049,390, Sep. 17, 1991, Liposome containing immunotherapy agents for treating IgE mediated allergies; Aristo Wojdani, 424/450 [IMAGE AVAILABLE]

US PAT NO: 5,049,390 [IMAGE AVAILABLE] L3: 17 of 39

ABSTRACT:

An immunotherapy agent for the treatment of allergy composed of an allergen encapsulated in or covalently bound to a liposome is disclosed.

Use of the agent in immunotherapy results in enhanced IgG production and reduced IgE production.

18. 5,037,846, Aug. 6, 1991, Indolyl-3 polyamines and their use as antagonists of excitatory amino acid neurotransmitters; Nicholas A. Saccomano, et al., 514/419; 548/495 [IMAGE AVAILABLE]

US PAT NO: 5,037,846 [IMAGE AVAILABLE] L3: 18 of 39

ABSTRACT:

This invention relates to certain polyamines found to be present in the

^\_venom^\_ of the Agelenopsis aperta spider. The polyamines of

this invention and the salts thereof antagonize excitatory amino acid neurotransmitters, which neurotransmitters affect cells of various organisms, and are useful in antagonizing said neurotransmitters, per se, in the treatment of excitatory amino acid neurotransmitter mediated diseases and conditions and in the control of invertebrate pests. This invention also relates to compositions comprising said polyamines and salts thereof.

19. 5,034,317, Jul. 23, 1991, Enzyme controlled release system and organic conjugate reactant; Michael J. Arnost, et al., 435/18, 4, 6, 14, 19, 21 [IMAGE AVAILABLE]

US PAT NO: 5,034,317 [IMAGE AVAILABLE] L3: 19 of 39

ABSTRACT:

The present invention provides an enzyme controlled release system and prepared reactant by which an identifiable molecule may be released on demand through the action of an active enzyme. The controlled release system is useful for detection of an analyte of interest present in a test sample in picogram per liter quantities and may be employed in a variety of different modes of use including immunoassays, enzyme amplification systems and the release of pharmacologically active ligands.

20. 5,021,576, Jun. 4, 1991, 2-Anilino phenylacetic acid derivatives;  
Amedeo A. Failli, et al., 546/174, 175 [IMAGE AVAILABLE]

US PAT NO: 5,021,576 [IMAGE AVAILABLE] L3: 20 of 39

ABSTRACT:

There are disclosed compounds of the formula ##STR1## wherein R is hydroxy, lower alkoxy or lower alkoxyamino;  
R<sup>sup.1</sup> is hydrogen or A(CH<sub>sub.2</sub>)<sub>sub.n</sub> O--;  
R<sup>sup.2</sup> is hydrogen or A(CH<sub>sub.2</sub>)<sub>sub.n</sub> O--, with the proviso that one of R<sup>sup.1</sup> and R<sup>sup.2</sup> is A(CH<sub>sub.2</sub>)<sub>sub.n</sub> O-- and the other is

hydrogen;

n is 1-2;

A is phenoxyethyl, phenoxyphenyl or a group having the formula ##STR2##

X is --N-- or ##STR3## Z is ##STR4## R<sup>sup.3</sup> is hydrogen, lower alkyl

or phenyl; R<sup>sup.4</sup> is hydrogen or lower alkyl; or

R<sup>sup.3</sup> and R<sup>sup.4</sup> taken together form a benzene ring;

R<sup>sup.5</sup> is hydrogen or lower alkyl;

R<sup>sup.6</sup> is hydrogen, halo or lower alkyl;

and the pharmacologically acceptable salts thereof, and their use in the

treatment of inflammatory conditions, such as rheumatoid arthritis,

ulcerative colitis, psoriasis and other immediate hypersensitivity

reactions; in the treatment of leukotriene-mediated naso-bronchial

obstructive air-passageway conditions, such as allergic rhinitis,

cytoprotective  
agents.

21. 5,013,830, May 7, 1991, Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers; Eiko Ohtsuka, et al., 536/27, 28, 29 [IMAGE AVAILABLE]

US PAT NO: 5,013,830 [IMAGE AVAILABLE] L3: 21 of 39

ABSTRACT:

There is disclosed a compound having a double chain which is composed of an RNA (+chain) and a complementary DNA (-chain), wherein a portion of the DNA (-chain) has been replaced by an RNA or a derivative thereof, and wherein, when the compound is subjected to the action of an enzyme having a ribonuclease H activity, it is possible to preferentially cleave the RNA (+chain) in a position corresponding to the unsubstituted portion of the DNA (-chain). The compound can thus be used for the preferential cleavage of a phosphodiester bond in a specific position of RNA. Accordingly, the invention provides a useful means for preparing, for

instance, a deletion mutant. There is also disclosed a mixed oligomer which comprises an oligomer of RNA or a derivative thereof and a DNA oligomer, wherein the RNA oligomer or a derivative thereof is conjugated to the DNA oligomer via a phosphate diester linkage between the 5'-hydroxyl group and the 3'-hydroxyl group in the ribose or deoxyribose moiety. There is further disclosed a nucleoside derivative of a given general formula for use as a starting material.

22. 4,960,712, Oct. 2, 1990, System and method for complement pathway analysis; Argyrios N. Theofilopoulos, et al., 436/501; 435/965, 973; 436/507, 512, 536, 539, 548, 804, 821 [IMAGE AVAILABLE]

US PAT NO: 4,960,712 [IMAGE AVAILABLE] L3: 22 of 39

ABSTRACT:

The present invention relates to systems and methods used to assay for particular complement component fragments. The invention can be used to determine the amount of a particular complement component fragment in a sample. The fragment can be fluid phase or bound to an immune complex. Generally, specific binding agents, such as antibodies, directed to the complement component fragments and immune complexes are used in the assay.

23. 4,946,788, Aug. 7, 1990, Purified immunoglobulin-related factor; novel monoclonal antibodies, hybridoma cell lines, processes and applications; Guy Delespesse, 530/388.22; 424/85.8; 435/7.5, 70.21, 172.2, 188, 240.27, 948, 964; 530/388.73, 391.3, 862, 866, 868; 935/95, 100, 102, 103, 104, 106, 107, 108, 110 [IMAGE AVAILABLE]

US PAT NO: 4,946,788 [IMAGE AVAILABLE] L3: 23 of 39

ABSTRACT:

The invention relates to novel purified human immunoglobulin E binding factors (IgE-BFs), its individual optionally glycosylated proteins, and

fragments thereof, processes for the purification of IgE-BFs, novel monoclonal antibodies to lymphocyte cellular receptors for IgE (Fc.sub.epsilon. R) crossreacting with IgE-Fs, derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines that produce these antibodies, processes for the preparation of said hybridoma cell lines, the use of the monoclonal antibodies and their derivatives for the qualitative and quantitative determination of IgE-BFs, test kits containing the monoclonal antibodies and/or their derivatives, the use of the monoclonal antibodies for the purification of IgE-BFs, the use of purified IgE-BFs, its individual optionally glycosylated proteins and/or fragments thereof for the

preparations containing them. IgE-BFs and monoclonal antibodies reacting with IgE-BF are important for the diagnosis and therapy of allergic diseases.

24. 4,880,817, Nov. 14, 1989, O-functionalized derivatives of substituted isoquinolin-3-ols having cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties;  
Ramesh M. Kanojia, et al., 514/309, 210, 235.2, 253; 544/120, 363;  
546/141

US PAT NO: 4,880,817 L3: 24 of 39

ABSTRACT:  
O-functional derivatives of substituted isoquinolin-3-ol compounds of the general formula ##STR1## that exhibit cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating are pharmacologically active in the treatment of cardiac conditions. Methods for synthesizing and using the compounds are described.

25. 4,867,973, Sep. 19, 1989, Antibody-therapeutic agent conjugates;  
John W. F. Goers, et al., 424/85.91, 85.8, 86, 87; 514/2, 6, 8;

530/388.7, 388.9, 391.9, 828, 864, 866; 930/10, 22

US PAT NO: 4,867,973 L3: 25 of 39

ABSTRACT:  
This invention relates to antibody-therapeutic agent conjugates having a therapeutic agent covalently attached to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody conjugates. Therapeutic in vivo methods utilizing such antibody-therapeutic agent conjugates are described.

26. 4,774,318, Sep. 27, 1988, Snake ^\_ venom ^\_ growth arresting peptide;  
Hans Marquardt, et al., 530/324, 325, 326, 856; 930/10, 260, DIG.821

US PAT NO: 4,774,318 L3: 26 of 20

ABSTRACT:

Novel cytotoxic agents are provided as small polypeptides related to a low molecular weight peptide derived from *Crotalus atrox*. The compounds may be used by themselves or in combination with other reagents, such as antibodies, for inhibiting cell growth.

27. 4,769,320, Sep. 6, 1988, Immunoassay means and methods useful in human native prothrombin and human abnormal prothrombin determinations; Bruce E. Furie, et al., 435/7.92, 7.23, 7.4, 13, 810; 436/69, 536, 548, 808, 811, 815, 825; 538/381, 384, 388.25, 808

US PAT NO: 4,769,320  
39

L3: 27 of

ABSTRACT:

Antibodies which form immune complexes with human native prothrombin only, in the presence of mixtures of human native prothrombin and human abnormal prothrombin as well as antibodies which form antibody antigen complexes with human abnormal prothrombin in the presence of such

mixtures have been obtained. Immunoassay techniques are used for qualitative and quantitative determinations of these antigens in

human plasma or serum. Unique methods of obtaining the antibodies are described including obtaining antibodies to native prothrombin by dissociation of antigen antibody complexes formed in the presence of calcium ions with a material having a greater affinity constant for binding with calcium ions than does prothrombin. Dissociation of the complex in this manner yields human native prothrombin antibodies which are specific and non-reactive with human abnormal prothrombin. A process is described in which assays are applied to the sensitive detection of vitamin K deficiency and various forms of liver disease including hepatocellular carcinoma, and to monitoring of anticoagulant therapy with sodium warfarin. The invention

20. 4,721,420, Mar. 15, 1988, Crataeo A\_ venom A\_ growth  
arresting peptide;  
Hans Marquardt, et al., 522/224; 424/25.01; 514/2, 12, 21;  
522/250, 401,  
405, 251; 522/13, 20, 210, 212.021

US PAT NO: 4,721,420 L3: 20 of  
29

ABSTRACT:  
Novel cytotoxic agents are provided as small polypeptides related  
to a  
low molecular weight peptide derived from Crataeo atrox. The  
compounds  
may be used by themselves or in combination with other reagents,  
such as  
antibodies, for inhibiting cell growth.

20. 4,714,725, Dec. 22, 1987, 4-nitrogen substituted  
isoquinolinel  
compounds having cardiotonic, phosphodiesterase fraction III  
inhibiting  
properties and/or renal vasodilating properties; Ramesh M.  
Kanejia, et  
al., 514/309; 546/141

US PAT NO: 4,714,725 L3: 29 of  
29

ABSTRACT:  
Substituted 3-isoquinolinel compounds of the general formula  
ABSTRACT:  
that exhibit cardiotonic and/or phosphodiesterase fraction III  
inhibiting  
properties and/or renal vasodilating are pharmacologically active  
in the  
treatment of cardiac conditions. Methods for synthesizing and  
using these  
compounds are described.

20. 4,675,287, Jan. 22, 1987, Monoclonal antibody directed to  
Lactam  
ganglioside GD.sub.2; Ralph N. Reisfeld, et al., 425/7.23;  
421/25.8,  
25.01; 425/7.02, 70.21, 172.2, 210.27, 210, 275; 421/510, 520,  
512, 212;  
522/227.5, 222.2, 222.25, 221.2, 222, 220, 225; 425/29, 25, 101,  
107

US PAT NO: 4,675,287 L3: 33 of  
33

ABSTRACT:

A non-human, mammalian monoclonal receptor produced and secreted by a hybridoma having the ATCC accession number HB 8568 and methods of preparing and using same, as well as diagnostics utilizing the receptor are disclosed. The monoclonal receptor reacts with cells such as human neuroectodermal tumors having ganglioside GD.sub.2 antigen expressed on their cellular membrane surfaces.

31. 4,672,044, Jun. 9, 1987, Murine monoclonal antibody combining site to human C3b receptor (CR1); Robert D. Schreiber, 436/501; 435/4, 7.21, 7.24, 7.25, 70.21, 172.2, 240.27, 810, 968, 975; 436/504, 506, 507, 512, 518, 536, 540, 548, 815, 821; 935/104, 110

US PAT NO: 4,672,044  
39

L3: 31 of

ABSTRACT:

A murine monoclonal antibody combining site produced by a hybridoma formed by fusion of cells from a myeloma cell line and lymphocytes that produce antibodies that react (1) with isolated human C3b receptor and

(2) with C3b receptor-bearing cells from a mammal immunized with human C3b receptor is disclosed.

32. 4,671,958, Jun. 9, 1987, Antibody conjugates for the delivery of compounds to target sites; John D. Rodwell, et al., 424/85.91, 1.1, 85.8, 86, 87; 514/2, 6, 8; 530/389.5, 391.5, 391.9, 828, 864, 866  
[IMAGE  
AVAILABLE]

US PAT NO: 4,671,958 [IMAGE AVAILABLE]  
39

L3: 32 of

ABSTRACT:

A method is described for the covalent attachment of linker groups to specific sites on antibody molecules directed against any desired target antigen (tumor, bacterial, fungal, viral, parasitic etc.). These

can be attached via amide or ester bonds to compounds for delivery which contain available amino or hydroxy groups (e.g., bioactive agents, cytotoxic agents, dyes, fluors, radioactive compounds, etc.). In addition the linkers can be incorporated into insoluble matrices for use in separation schemes which are based upon antibody-antigen interactions. The linkers may be designed so that they are susceptible to cleavage by any one of the serum complement enzymes. When prepared according to the methods described herein, the resulting modified antibody molecule retains the ability to bind antigen and to fix serum complement. Thus, when administered to a patient the antibody conjugate binds to its target in vivo. As a result of the subsequent activation of the patient's serum complement, the covalently attached compound will be specifically cleaved at the target site by the proteolytic enzymes of the complement system.

33. 4,661,347, Apr. 28, 1987, Cytotoxic compositions; Hans J. Muller-Eberhard, et al., 424/85.91; 435/188; 530/388.85, 391.7, 391.9, 395, 402, 403, 404, 408

US PAT NO: 4,661,347  
39

L3: 33 of

#### ABSTRACT:

A cytotoxic composition is described comprising a moiety having binding affinity to a surface structure of a cell and coupled to a moiety having activity as a structural subunit of C3/C5 convertase.

34. 4,642,284, Feb. 10, 1987, Method and system for detection of complement pathway activation; Neil Cooper, et al., 435/7.94, 4, 7.4, 28, 965, 966, 971, 975; 436/512, 518, 520, 528, 529, 530, 536, 538, 540, 543, 544, 547, 808, 821

US PAT NO: 4,642,284  
39

L3: 34 of

#### ABSTRACT.

A method and system for detecting and preferably measuring the presence of an activated complement complex in a sample is discussed. The presence of such an activated complex is indicative of complement pathway activation and includes a first complement component and a second complement component. The method uses a first binding agent specific to the first complement component and a second binding agent specific to the second complement component which when bound with the complex forms an aggregate. The second specific binding agent includes a label whose presence is used to detect and measure the amount of aggregate and therefore activated complex in a sample. An assay system and aggregate for use in an assay system are also discussed.

35. 4,517,303, May 14, 1985, Specific binding assays utilizing analyte-cytolysin conjugates; J. William Freytag, et al., 436/501; 435/4, 5, 7.21, 7.22, 7.23, 7.25, 7.31, 7.32, 7.5, 7.8, 7.9, 21, 36, 966, 972; 436/512, 520, 541, 803, 813, 815, 817, 827, 828, 829; 930/10, 240, 200, DIG.821 [IMAGE AVAILABLE]

US PAT NO: 4,517,303 [IMAGE AVAILABLE] L3: 35 of 39

#### ABSTRACT:

A novel analyte-cytolysin conjugate and its use in a lipid vesicle mediated measurement process is described for a wide variety of analytes present at very low concentration. The method involves forming a reaction system consisting of analyte, analyte specific binding agent, analyte-cytolysin conjugate, and vesicles containing detectable marker material in such proportions that uncombined conjugate alters the permeability of the vesicles resulting in the release and quantitative detection of marker material which can be correlated with the amount of analyte initially present.

36. 4,454,226, Jun. 12, 1984, Enzymatic immunoassay; Majid Ali, et al., 435/4, 5, 7.21, 7.22, 7.23, 7.25, 7.31, 7.32, 7.5, 7.8, 7.9, 21, 36, 966, 972; 436/512, 520, 541, 803, 813, 815, 817, 827, 828, 829; 930/10, 240, 200, DIG.821 [IMAGE AVAILABLE]

## ABSTRACT:

An enzyme immunoassay for detecting an antigen in a biologic fluid or tissue which comprises contacting the fluid or tissue with an antibody specific for the antigen under binding conditions, at least one of the fluid or tissue and antibody having a solid component, contacting the resulting solid with a conjugate bindable with the antibody under binding conditions and determining the enzyme activity of the resulting solid phase is described. The conjugate is of peroxidase and an allergen, non-immunoglobulin protein or primary amino group containing drug having an average of 2-3 molecules of peroxidase per molecule of substance with an average molecular weight of about 30,000 daltons, prepared by reacting peroxidase previously treated with phenyl isothiocyanate and oxidized to form aldehyde groups with the substance to form a Schiff's base which is titrated with a reducing agent to form a stable conjugate.

37. 4,447,526, May 8, 1984, Homogeneous specific binding assay with carrier matrix incorporating specific binding partner; Patricia A. Rupchock, et al., 435/7.7; 422/56; 435/7.72, 7.92, 885, 971; 436/528, 530, 535, 537, 810

## ABSTRACT:

A method for determining the presence of a ligand in, or the binding capacity of a liquid test sample which includes the steps of (a) adding to the sample a conjugate of the ligand and a label, (b) contacting the sample with a test device containing reagents which in conjunction with the conjugate and ligand, are capable of producing a detectable response and (c) measuring the response.

29. 4,446,245, May 4, 1984, Adenosine  
5'-triphosphate-carbamidate-  
2'-phosphate; Winkler, Victor E. Marquies, et al., 531/227, 29

US PAT NO: 4,446,245 L2: 20 of  
29

ABSTRACT:  
The present invention relates to the preparation of and the  
antitumor  
compound, adenosine 5'-trihydrogen diphosphate  
5'-adenosine-5'-ester with  
4-carbamidate-2-beta, -2-mitofuranosylthiazole.

29. 4,420,495, Feb. 7, 1984, Process for preparing lincosycin  
and  
clindamycin ribonucleotides; Ted E. Patt, et al., 535/16.2, 16.2,  
16.4,  
16.5, 29, 29

US PAT NO: 4,420,495 L2: 39 of  
29

ABSTRACT:  
Novel and useful ribonucleotides of analogs of the well known  
antibiotics  
lincosycin and clindamycin. These ribonucleotides are  
unexpectedly highly  
active against Streptococcus hemolyticus and Staphylococcus  
aureus in  
vivo. These ribonucleotides are prepared by using resting cell or

cell-free extracts of Streptococcus rochei, NRRL 2522, or  
cell-free  
extracts of Streptococcus bovicola, NRRL 2522.

=> d his

(FILE NUMBER ENTERED AT 11:34:27 ON 24 FEB 92)

L1 682 G VENOM OR ANTIVENIN  
L2 2470 G FAD OR FAD2  
L3 20 G L2 AND L1

=> s 12 and polyacrylamide  
12911 POLYACRYLAMIDE  
L4 270 L2 AND POLYACRYLAMIDE

=> s 14 and (papain or papain)  
1012 PAPAIN  
1265 PAPAIN  
L5 152 L4 AND PAPAIN OR PAPAIN

75. 4,897,466, Jan. 30, 1990, Human lymphoblastoid cell line and hybridomas derived therefrom; James W. Larrick, et al., 424/85.8; 530/809; 935/107

=> t15 100 cit  
'TL5' IS NOT A RECOGNIZED COMMAND

=> t 15 100 cit

100. 4,772,550, Sep. 20, 1988, Heterogeneous specific binding assay employing an aggregatable binding reagent; Alfred C. Greenquist, 435/7.92, 7.5, 7.93, 7.94, 280, 805, 810; 436/503, 524, 529, 533, 534, 539, 808, 810, 824

=> t 15 125 cit

125. 4,614,793, Sep. 30, 1986, Hepatitis A--subunit antigen; Joseph V. Hughes, et al., 530/350, 418, 806, 826; 930/223

=> t 15 140 cit

140. 4,429,008, Jan. 31, 1984, Thiol reactive liposomes; Frank J. Martin, et al., 428/402.2; 424/1.1, 85.8, 88, 450; 436/501, 532, 829  
IMAGE AVAILABLE

=> t 15 140 -152 cit at  
'-152' IS NOT A VALID FORMAT FOR FILE 'USPAT'  
ENTER DISPLAY FORMAT (CIT):140-152  
'140-152' IS NOT A VALID FORMAT FOR FILE 'USPAT'  
YOU HAVE RECEIVED THIS ERROR MESSAGE 2 CONSECUTIVE TIMES

The following are valid formats:

PNO ----- Patent Number  
PAT ----- Patent Number, Issue Date, and Current Original  
            Reference Classification  
CIT ----- Patent Number, Issue Date, Title,  
            First Inventor Name, and Current Classifications  
LEG ----- Patent Number, Issue Date, Title, Inventor, Assignee,  
            Appl. Number, Filing Date, Art Unit, Primary Examiner,  
            Legal Rep., Rule 47 Indicator, Attorney Reg. Number  
REF ----- Classification and Reference Information  
DATE ----- PCT Information and all dates from Front Page  
PCT ----- Alias for the DATE Format  
BIB ----- Alias for the LEG Format  
FRD ----- Front Page Information, Art Unit, and Current  
            Classification

ALL ----- Entire Patent and Key words assigned  
 FUL ----- Alias for the ALL Format  
 SPC ----- Alias for the ALL Format  
 CLS ----- Patent Number and Current Classification  
 PN ----- Patent Number  
 OCC ----- Occurrence Count  
 AB ----- Abstract  
 FD ----- Application Filing Date  
 AD ----- Application Filing Date  
 AN ----- Application Number  
 ART ----- Art Unit  
 AS ----- Assignee Information  
 ATT ----- Attorney, Agent or Firm  
 BSUM ----- Summary  
 CCLS ----- Current Classification  
 CLMS ----- Claims Information  
 D371 ----- PCT 371 Date  
 DD ----- Disclaimer Date  
 DETD ----- Detail Description  
 DRWD ----- Drawing Description  
 E102 ----- PCT 102(e) Date  
 ECL ----- Exemplary Claim Number  
 FREF ----- Foreign Patent References Cited  
 FS ----- Field of Search Subclasses  
 GI ----- Government Interest Text Data  
 ICLS ----- Issue Classification  
 IN ----- Inventor Information  
 IPC ----- International Classification  
 GREF ----- Other Publication References Cited  
 PARN ----- Parent Case Text Data  
 PD ----- Issue Date  
 PPDR ----- Number of Drawing Sheets

PPSP ----- Number of Specification Pages  
 PRIR ----- Foreign Application Priority  
 PTAN ----- PCT Number  
 PTFD ----- PCT Filing Date  
 PTPD ----- PCT Publication Date  
 PTPN ----- PCT Publication Number  
 REI ----- Reissue Data  
 REL ----- Related Application Data  
 TERM ----- Term Of Patent  
 TI ----- Title  
 UREF ----- U. S. Patent References Cited  
 XA ----- Assistant Examiner  
 XP ----- Primary Examiner  
 KEY ----- Keywords Identified for Patent  
 IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK  
 ENTER DISPLAY FORMAT (CIT):  
 ENTER DISPLAY FORMAT (CIT):cit

140. 4,429,008, Jan. 31, 1994, Thiol reactive liposomes; Frank J. Martin, et al., 428/402.2; 424/1.1, 85.8, 88, 450; 436/501, 532,

[IMAGE AVAILABLE]

=> t 15 cit 140-152

140. 4,429,000, Jan. 31, 1984, Thiol reactive liposomes; Frank J. Martin, et al., 426/402.2; 424/1.1, 85.8, 88, 450; 436/501, 532, 829

[IMAGE AVAILABLE]

141. 4,421,735, Dec. 20, 1983, Radiolabeled diagnostic compositions and method for making the same; Edgar Haber, et al., 424/1.1, 9; 530/382, 389.1, 389.2, 389.7, 391.5, 392, 404, 405, 406, 409 [IMAGE AVAILABLE]

142. 4,400,376, Aug. 23, 1983, Immunological preparations; Arnold R. Sanderson, 424/88, 85.8, 86, 87, 89, 91, 92; 436/543; 530/388.2, 388.73, 389.2, 389.4, 389.5, 389.6, 391.9, 405, 806, 807, 866

143. 4,375,972, Mar. 8, 1983, Heterogeneous chemiluminescent immunoassays utilizing metallo porphyrin tag; Peter S. Forgione, et al., 436/531, 546

144. 4,368,149, Jan. 11, 1983, Protein hybrid having cytotoxicity and process for the preparation thereof; Yasuhiko Masuho, et al., 530/391.9;

424/85.91, 88; 530/389.6, 391.7, 866; 935/107

145. 4,366,241, Dec. 28, 1982, Concentrating zone method in heterogeneous immunoassays; Henry K. Tom, et al., 435/7.91; 422/56; 435/5, 7.9, 7.92, 805, 810, 958, 975; 436/541, 800, 807

146. 4,363,750, Dec. 14, 1982, Cytotoxic protein hybrid and process for the preparation thereof; Yasuhiko Masuho, et al., 530/391.9; 424/85.91, 88; 435/172.2; 530/370, 379, 389.6, 391.7, 866; 935/107, 108

147. 4,357,273, Nov. 2, 1982, Antitumor protein hybrid and process for the preparation thereof; Yasuhiko Masuho, et al., 530/391.9; 435/172.2; 514/12; 527/203; 530/389.3, 389.7, 806, 825, 866; 935/107, 108

148. 4,350,626, Sep. 21, 1982, Antitumor hybrid and process for the

4,325,427, Oct. 20, 1980, Polymers having thiol reactive groups;  
425/427.2;  
520/300.4, 511, 425/427

140. 4,306,027, Oct. 20, 1980, Dye intermediates having thiol reactive groups;  
425/427.2; Richard M. Smith, 520/300.4, 424/427.2, 520/300

150. 4,272,524, Jan. 6, 1980, Polymers having thiol reactive groups;  
425/427.2; Moshe Schwartzberg, 425/427.2, 520/300, 424/427.2, 520/300, 425/427.2, 511, 520, 425/427.2, 511, 520, 525, 520/300.4, 300.5, 301.4, 301.5, 301.6, 404, 412, 512, 511 [IMAGE AVAILABLE]

151. 4,222,402, Nov. 11, 1980, Reagents and method employing channeling;  
Edward T. Maggio, et al., 425/427.2, 7.7, 7.91, 060, 425/427.2, 525

152. 4,024,915, Jul. 19, 1977, Composition and method for determining the size and location of myocardial infarcts; Edgar Haber, 424/427.2;  
420/454; 520/300; 424/9 [IMAGE AVAILABLE]

=> to 15 cit at 140-152

140. 4,420,000, Jan. 31, 1980, Thiol reactive liposomes; Frank J. Martin, et al., 420/400.2; 424/1.1, 55.8, 50, 450; 425/401, 520, 520  
[IMAGE AVAILABLE]

US PAT NO: 4,420,000 [IMAGE AVAILABLE] LS: 140 of 152

ABSTRACT:  
Liposomes are provided which have a plurality of thiol reactive groups extending outward of the liposomal bilayer. The liposomes form stable covalent bonds with ligands having thiol groups, such as antibodies, antigens, and targeting to specific cells. Particularly preferred liposomes include calcium phosphate liposomes. The thiol reactive liposomes are especially employed in agglutination assays, such as blood typing and blood typing, and targeting to specific cells.

141. 4,401,735, Dec. 20, 1980, Radiolabeled diagnostic compositions and

530/382,  
389.1, 389.2, 389.7, 391.5, 392, 404, 405, 408, 409 [IMAGE  
AVAILABLE]

US PAT NO: 4,421,735 [IMAGE AVAILABLE] LS: 141 of  
152

ABSTRACT:

Protein molecules are covalently bonded to a chelating agent which in turn binds a radioactive molecule. Prior to binding, the radioactive molecule is reduced with dithionite ion and then mixed with protein at a pH of 7.0 to about 8.0.

142. 4,400,376, Aug. 23, 1983, Immunological preparations; Arnold R. Sanderson, 424/88, 85.8, 86, 87, 89, 91, 92; 436/543; 530/388.2, 388.73, 389.2, 389.4, 389.5, 389.6, 391.9, 405, 806, 807, 866

US PAT NO: 4,400,376 LS: 142 of  
152

ABSTRACT:

An immunological preparation of an antigenic material in combination with a major histocompatibility complex antigen, which is itself in the form of complex with a protein with which it is normally

associated in nature or with a modified form of such protein which retains the epitope thereof intact, said antigenic material being attached to the protein of the complex through antibody to that protein, is disclosed as being useful for the production of an immunogenic response in human or veterinary use.

143. 4,375,972, Mar. 8, 1983, Heterogeneous chemiluminescent immunoassays utilizing metallo porphyrin tag; Peter S. Forgiione, et al., 436/531, 546

US PAT NO: 4,375,972 LS: 143 of  
152

ABSTRACT:

A conjugate for use in the detection and quantification of antibodies and

chemiluminescent immunoassay procedures utilizing the conjugate. The conjugate is capable of reacting with an antigen or an antibody or both and includes a tag capable of catalyzing a chemiluminescent reaction. The conjugate may be an antibody or an antigen to which a metallo porphyrin tag is attached and preferably comprises immunoglobulin to which hemoglobin is attached.

144. 4,368,149, Jan. 11, 1983, Protein hybrid having cytotoxicity and process for the preparation thereof; Yasuhiko Masuho, et al., 530/391.9; 424/85.91, 98; 530/389.6, 391.7, 866; 935/107

US PAT NO: 4,368,149 LS: 144 of 152

ABSTRACT:

A protein hybrid having cytotoxicity obtained by covalently bonding an immunoglobulin or its fragment, which is capable of binding selectively to an antigen possessed by a cell to be destroyed, to a protein, which is obtained from Momordica charantia and has an activity to terminate protein synthesis. This protein hybrid displays remarkable cytotoxicity

against target cells.

145. 4,366,241, Dec. 28, 1982, Concentrating zone method in heterogeneous immunoassays; Henry K. Tom, et al., 435/7.91; 422/56; 435/5, 7.9, 7.92, 805, 810, 960, 975; 435/541, 900, 807

US PAT NO: 4,366,241 LS: 145 of 152

ABSTRACT:

Method and apparatus are provided for performing immunoassays employing a device comprising a relatively small test zone referred to as an immunosorbing zone, and a relatively large liquid absorbing zone in liquid receiving relationship with said immunosorbing zone. The immunosorbing zone includes a member of an immunological pair ("mip")--ligand and antiligand--bound to a support. A signal producing system is employed in conjunction with said device

having as one component a signal label bound to a site on the signal  
producing system provides for production of a detectible signal  
in the  
immunosorbing zone in relation to the amount of analyte in a  
sample.

146. 4,363,758, Dec. 14, 1982, Cytotoxic protein hybrid and  
process for  
the preparation thereof; Yasuhiko Masuho, et al., 530/391.9;  
424/85.91;  
88; 435/172.2; 530/370, 379, 389.6, 391.7, 866; 935/107, 108

US PAT NO: 4,363,758  
152

LS: 146 of

ABSTRACT:

A cytotoxic protein hybrid obtained by covalently bonding an  
immunoglobulin or its fragment, which is capable of linking  
selectively  
with an antigen possessed by a cell to be destroyed, to a  
protein, which  
is obtained from *Phytolacca americana* and has an activity to  
terminate  
protein synthesis. This protein hybrid displays remarkable  
cytotoxicity  
against target cells.

147. 4,357,273, Nov. 2, 1982, Antitumor protein hybrid and  
process for  
the preparation thereof; Yasuhiko Masuho, et al., 530/391.9;  
435/172.2;  
514/12; 527/203; 530/389.3, 389.7, 806, 825, 866; 935/107, 108

US PAT NO: 4,357,273  
152

LS: 147 of

ABSTRACT:

Antitumor protein hybrid, composed of a moiety which is  
substantially the  
fragment  $\text{^}_\text{Fab} \text{^}$  of an anti- $\alpha$ -fetoprotein antibody and  
a moiety  
which is substantially the fragment A of a diphtheria toxin,  
which is  
expressed by the following formula (I):

$\text{^}_\text{Fab} \text{^} \text{---} (\text{S.sub.1} \text{---} (\text{X}).\text{sub.n} \text{---} \text{S.sub.2} \text{---} \text{FA}).\text{sub.m}$   
(I)

(where  $\text{^}_\text{Fab} \text{^}$  indicates a moiety which is substantially the  
fragment

$\text{^}_\text{Fab} \text{^}$  of an anti- $\alpha$ -fetoprotein antibody; FA indicates  
a moiety  
which is substantially the fragment A of diphtheria toxin; X  
indicates a

atoms,  
 S.sub.1 indicating a sulfur atom arising from the disulfide bond  
 (—S—S—bond) in an anti- $\alpha$ -fetoprotein antibody and  
 S.sub.2 a  
 sulfur atom arising from the disulfide bond in a diphtheria  
 toxin; n  
 stands for 0 or 1 and m stands for an integer of 1 to 5). This  
 antitumor  
 protein hybrid has remarkable and specific cytotoxicity against  
 tumor  
 cells.

148. 4,350,626, Sep. 21, 1982, Antitumor hybrid and process for  
 the  
 preparation thereof; Yasuhiko Masuko, et al., 530/391.9;  
 435/172.2;  
 530/389.6, 866; 935/107

US PAT NO: 4,350,626  
 152

LS: 148 of

# ABSTRACT:

Antitumor protein hybrid, composed of a moiety which is  
 substantially the  
 fragment  $\wedge$  Fab  $\wedge$  of an antitumor immunoglobulin and a moiety  
 which is the  
 subunit A of ricin, which is expressed by the following formula  
 (I):

$\wedge$  Fab  $\wedge$  (S.sub.1 —(X).sub.n —S.sub.2 —RA).sub.m  
 (I)

(where  $\wedge$  Fab  $\wedge$  indicates a moiety which is substantially the

fragment  
 $\wedge$  Fab  $\wedge$  of an antitumor immunoglobulin; RA indicates a moiety  
 which is the  
 subunit A of ricin; X indicates a divalent organic radical;  
 S.sub.1 and  
 S.sub.2 are both sulfur atoms, S.sub.1 indicating a sulfur atom  
 arising  
 from the disulfide bond (—S—S— bond) in an immunoglobulin and  
 S.sub.2  
 a sulfur atom arising from the disulfide bond in ricin; n stands  
 for 0 or  
 1 and m stands for an integer of 1 to 5). This antitumor protein  
 hybrid  
 has remarkable and specific cytotoxicity against tumor cells.

149. 4,296,027, Oct. 20, 1981, Pure intravenous human and animal  
 gamma  
 globulins; Richard M. Condie, 530/390.5; 424/85.5; 530/830

US PAT NO: 4,296,027  
 152

LS: 149 of

ABSTRACT:

Isolated and purified natural, unaltered, undenatured immune gamma globulin (IgG) for intravenous administration prepared from animal blood plasma, especially human. The products are characterized by high yield and high purity. They are unfragmented and unaggregated, i.e., natural preparation.

150. 4,272,506, Jun. 9, 1981, Purification of reagents by disulfide immobilization; Moshe Schwarzberg, 435/512; 250/382; 424/1.1, 88; 435/4, 962, 964, 968; 436/513, 546, 800, 825; 530/389.1, 389.3, 391.1, 391.3, 404, 413, 813, 861 [IMAGE AVAILABLE]

US PAT NO: 4,272,506 [IMAGE AVAILABLE] LS: 150 of 152

ABSTRACT:

A method is provided for preparing immunoassay reagents involving labeled members of specific binding pairs substantially enriched relative to contaminating labeled materials. The method involves conjugating a member of a specific binding pair to a support by a covalent bond which is cleavable under mild conditions to provide a binding pair

member-support conjugate. Combining the binding pair member-support conjugate with a labeled composition containing the reciprocal member of the binding pair, so that the labeled reciprocal member becomes bound to the support through the binding of the specific binding pair. Separating the support to which is bound the labeled member from the remaining labeled material and then cleaving the bond joining the labeled specific binding pair to the support to provide labeled reagent for immunoassays. In particular, an antibody is linked to a support by disulfide linkage and a composition containing the reciprocal antigen to the antibody is labeled with a chromophore, particularly fluorescein. The support is freed of labeled

link  
cleaved to provide labeled reagent for immunoassays.

151. 4,233,402, Nov. 11, 1980, Reagents and method employing channeling;

Edward T. Maggio, et al., 435/5, 7.7, 7.91, 968; 435/537, 885

US PAT NO: 4,233,402  
152

LS: 151 of

ABSTRACT:

Method and compositions are provided for chemical analysis of an analyte

which is a member of a specific binding pair of organic substances

consisting of ligand and ligand receptor (antiligand). The method

involves bringing together the following reagents with the analyte in an aqueous assay medium under mild conditions.

The first reagent is a conjugate of a member of the specific binding pair

with a chemical entity which provides a means for chemically changing the

concentration of a compound which acts as a signal mediator. The second

reagent is the signal mediator precursor. The third reagent is a conjugate of a member of the specific binding pair with a component of a

signal producing system of which system the signal mediator is a member.

The amount of signal which can be detected is affected by the

local

concentration of the signal mediator. By bringing the reagents together

in the presence of analyte, where the signal mediator concentration

changing means is brought together in a microenvironment with the

conjugated signal producing system component, localized concentrations of

the signal mediator can be created which differ from the gross concentration of the signal mediator in the assay medium. The degree to

which the signal mediator concentration changing means is in close

proximity to the signal producing means in a microenvironment will affect

the observed signal. By appropriate choice of the two conjugates in

conjunction with the analyte, the observed signal can be related to the

amount of analyte in the medium.

conjugates in specific proportions to substantially optimize the assay sensitivity. The combinations are provided as kits, where ancillary reagents can also be included, so as to simplify the combination of reagents, as well as provide for more accurate measurements and relative proportions of reagents.

152. 4,036,945, Jul. 19, 1977, Composition and method for determining the size and location of myocardial infarcts; Edgar Haber, 424/1.1; 128/654; 250/303; 424/9 [IMAGE AVAILABLE]

US PAT NO: 4,036,945 [IMAGE AVAILABLE] LS: 152 of 152

ABSTRACT:

Radioactive labelled antibody for cardiac myosin is injected intravenously after cardiac occlusion and is specifically absorbed in infarcted myocardium, as are radioactive labelled lower molecular weight fragments of the antibody such as ( ^\_ Fab ^\_ ' ).sub.2, ( ^\_ Fab ^\_ ' ), and (Fv). The location and size of the myocardial infarct can be determined by measuring the intensity and location of radioactive emission externally

of the heart.

=>